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Hepatitis C virus (HCV) infection is the leading cause of cirrhosis, hepatocellular 
carcinoma, and liver transplantation. Current treatment rates and efficacy are 
inadequate to manage the disease burden caused by HCV; thus, efforts are needed 
to control HCV transmission. Besides the well-known transmission routes, which are 
health-care-associated transmission and transmission through injecting drugs, HCV 
could also be transmitted by sexual contact, especially among men having sex with 
men (MSM). MSM also have higher drug use prevalence than the general 
population, which may contribute to HCV infection by sexual disinhibition and other 
risky behavior.  Since 2000, there have been emerging reports indicating HCV 
epidemics or outbreaks among HIV positive MSM in Europe, Australia and North 
America. However, previous studies often focused on HIV positive and/or injection 
drug using MSM, and there is still a need for study targeting on non-injection drug 
using MSM. The overall objective of this study is to investigate characteristics 
associated with HCV infection in MSM who used drugs but not injected drugs (NIDU 
MSM).  
  
This study used data from two projects, DASH project and YMAP project, and 
applied latent class analysis and dyadic data analysis to analyze the data. The main 
finding of this study included: (1) overall HCV prevalence in NIDU MSM was higher 
than the rest of general population; (2) NIDU MSM >=42 years old had a higher risk 
of HCV infection than NIDU MSM <42 years old; (3) NIDU MSM >=42 years old who 
used >6 drugs were associated with increased probability of HCV infection among all 
NIDU MSM; (4) among NIDU YMSM, syphilis mono-infection, HIV mono-infection, 
and syphilis/HIV co-infection were associated with increased risk of HCV infection. 
This study may provide a better understanding of HCV transmission among NIDU 
MSM. These results may provide a profile of subgroups with a higher HCV 
transmission possibility among NIDU MSM. In the long term, the results of the study 
may guide the development of healthcare and behavioral intervention programs 
related to HCV transmission, and may also guide tailored screening or treatment 
strategies for HCV infection. 
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BACKGROUND 
Background and literature Review  
Hepatitis C Virus infection 
Hepatitis C virus (HCV) infection affects primarily the liver and causes acute and chronic 
hepatitis in humans with a high propensity for chronicity. [1] It has become a leading 
cause of cirrhosis, hepatocellular carcinoma, and liver transplantation. [2]  
Worldwide, three to four million people are newly infected each year and 170 million 
people are chronically infected accounting for 3% of the global population. [3] In the 
United States, it is estimated that 3.5 million people are living with HCV infection, which 
accounts for about 1% of the population. [4] The number of estimated new annual HCV 
infections increased from 16,500 in 2011 to 41,200 in 2016 [5], tripling in six years. 
Young people ages 20-29 years who inject drugs account for the greatest increases, 
and the highest overall number of cases. [5] 
Among infected individuals, about 25% could spontaneously eliminate the virus, and the 
remaining 75% are chronically infected. Of those with chronic HCV infection, the risk of 
cirrhosis of the liver is between 15–30% within 20 years. [6] Worldwide, about 399,000 
people die each year due to all HCV-related causes, mainly from HCV-related cirrhosis 
and hepatocellular carcinoma. [7]  
The current treatment paradigm can achieve 95% cure rates. [8] However, these 
medicines are very expensive in many high- and middle-income countries, which 
creates a major barrier for people with HCV infection to obtain access to proper 
treatment. Meanwhile, the rate of access to diagnosis and treatment is low. In 2015, of 
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the people living with HCV globally, 20% knew their diagnosis, and only 7.4% of those 
diagnosed were started on treatment in 2015 [7]. A study modeling current and future 
disease burden of HCV indicates that the current treatment rate and efficacy are 
inadequate to reduce the disease burden of HCV; thus, more efforts are needed to 
control HCV transmission. [9] 
HCV can be transmitted from one individual to another through bodily fluids. The 
first transmission route has proven to be health-care-associated transmission, such as 
unsafe injection practices and procedures. [10] Approximately half of the chronic 
infection happened through this transmission route in developing countries. [9] The 
second transmission route is well considered to be transmission among people who 
inject drugs through unsterile injection equipment and contaminated drug solutions. 
According to a systematic review, this route primary contributed to the infection, 
especially incident infection, in middle- and high-income countries [11]. The third 
transmission route could be sexual transmission. Since 2000, there has been increasing 
reports of HCV epidemic among HIV positive MSM in Northern Europe, North America, 
and Australia [12-15], linked to high-risk sex behaviors and potentially underreported 
non-injection drug use [16, 17]. 
HCV among people who use drugs 
There is a high prevalence of illicit drug use in the United States and the prevalence has 
been increasing in recent decades. Approximately 29.5 million aged 12 years or older 
(0.6% of the population) are suffering from drug use disorders [18]. In 2014, in North 
America, the drug-related death rate is 164.5 /per million among 15-64 years, 3.5 times 
than the global average number.  
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Among people who use drugs, about one third are injection drug users (IDU) [19] 
constituting the “core” population of HCV infection. Among IDU 40%-90% are infected 
by HCV, and IDU accounted for more than 50% of all cases of HCV. [20] For non-
injection drug users (NIDU), less attention was paid to their HCV infection. One 
systematic review, however, reported that the HCV prevalence ranged from 2.3% to 
35.3% in NIDU and is much higher than the prevalence in the non-drug using 
population. [21]  
HCV among MSM 
There are an estimated 8.4 million MSM in the US [22], of whom 16% are infected with 
HIV [23]. During the last decade, there have been increasing reports of acute HCV 
epidemic among MSM in Western countries. [13, 14, 24-26] One recently published 
systematic review and meta-analysis, which quantitatively synthesized 28 studies since 
2000, reported that the pooled estimated incidence rate was 6.4 per 1000 person-year 
(95%CI: 5.0-7.5), and the incident rate of HCV among HIV positive MSM was 19 times 
than that of HCV among HIV negative MSM. [27] Another recently published systematic 
review and meta-analysis, which quantitatively synthesized 42 studies from 1990 to 
2015, studied HCV prevalence among HIV positive MSM and reported that the pooled 
hepatitis C virus prevalence was 8.1%. [28]  
It is believed that HCV was first introduced in this population by parenteral transmission 
through injection drug use [14, 29, 30], then researchers proved HCV transmission 
network among MSM by using phylogenetic approaches [17] and sexual transmission 
was thought to be the most possible transmission mechanism [12].  
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In this population, researchers revealed that the HCV epidemics have been associated 
with behavioral factors (such as group sex, recreational drug use, sex with drug use, 
sex practices disrupting the anal mucosal), and biological characteristics (such as HIV 
co-infection, and recent history of syphilis). [27, 31]  
HCV among MSM who use drugs   
Research suggests that MSM are more likely to use drugs compared to adults in the 
general population. According to a National Household Survey on Drug Abuse, the 
prevalence of drug use in the past month is 16.3% among MSM, while 9.9% among 
men only having female partners. [32] A national MSM sample found a 42% previous 
year prevalence for any non-injection substance use. [33] This higher rate of drug use 
can be a reaction to homophobia, discrimination, or violence that MSM experience 
because of their sexuality. [34] One systematic review and meta-analysis, targeted only 
HIV positive MSM, reported that the pooled HCV prevalence was 40% among IDU and 
was 6.7% among NIDU, and the prevalence was increasing over time among both 
subgroups. [28] 
Summarizing various studies, there are three distinct characteristics of drug use 
behavior among MSM. First, most drug use MSM are not drug-dependent, but rather 
use episodically (i.e., using substances less than weekly). National HIV Behavioral 
Surveillance (NHBS) data show that 69%–86% of drug use MSM report less than 
weekly substance use [32–35]. This pattern perhaps less concerning from a drug-
dependence perspective, however, is associated with high-risk sexual behaviors [24, 
38]. Second, drug use MSM are more likely to use drugs related to sex (meth, EDDs, 
poppers), or club drugs (Ketamine, MDMA, GHB, etc.), which are related to high-risk 
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sexual behaviors and contribute substantially to HIV transmission rates. Third, multiple 
drug use (i.e. taking more than one substance at the same time or periodically over a 
period of time) is very common among drug using MSM.  For example, in the San 
Francisco NHBS sample, more than 90% of Methamphetamine, cocaine or popper 
using MSM reported using other substances. In a sample of MSM from San Diego, who 
were HIV positive and used methamphetamine, 95% used multiple drugs. Two studies 
in New York targeting club drug using MSM, reported similar findings. Among various 
drug using MSM samples, 11%-44% of respondents reported recent use of more than 
three substances. 
It is biologically plausible that mucosally administered drug use may directly be 
associated with HCV infection by sharing insertion equipment, mucosal trauma and 
mucosal hyperemia. [35] Drug using may also alter mental status, decrease pain, 
improve sexual function or desire, therefore drug-using MSM may get involved in riskier 
sexual behaviors, such as multiple sex partners, marathon sex, anonymous sex, low 
condom use, and other risk behaviors, such as exchange sex for drugs and money, and 
sharing needles when injecting drugs. Those risk behaviors substantially contribute to 
the transmission of HIV, Hepatitis, and other STDs. However, it is difficult to disentangle 
the extent to which non-injecting drug use directly facilitates HCV infection versus the 
effect of disinhibiting riskier sexual behaviors.  
There are case-control studies of HIV positive MSM from UK and German, showing 
higher levels of nasally administrated drug use in HCV cases than in controls. [15, 36] 
One study in the US indicated that methamphetamine use during sex was the most 
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significant risk factor for HCV transmission in non-injection drug use, HIV-positive MSM. 
[37]  
There is a need for more understanding the practice associated with HCV infection in 
NIDU MSM, which could lead to better informed and more effective prevention. This 
proposed study intended to use traditional epidemiology method and latent class 
analysis to explore risk factors associated with HCV infection in NIDU MSM, and to use 
a social network analysis approach to evaluate risk factors associated with HCV 
infection in NIDU MSM. 
Latent class analysis 
Latent class analysis (LCA) is a statistical model, in which several items are used to 
determine the class of individuals. [38, 39] The hypothesis of LCA is the similarity of the 
response for the individuals within a class. [40] LCA assumes homogeneity within a 
class, heterogeneity among classes, and that the difference in response to items within 
a class is only due to random error. [39, 40] Different from cluster analysis, which is not 
a statistical model, LCA can provide not only the results of classification but also the 
probability that one individual belongs to a certain class. In addition, LCA can provide 
the probability that one individual belongs to a certain class given a “yes” response to a 
certain item. 
People who use drugs often use different kinds of drugs, by multiple routes of 
administrations (for example smoking, chewing, swallowing, snorting, inhaling or taking 
in pill form ), and patterns of substance use vary among different populations [41]. Drug-
using MSM are also not a homogeneous population. Only focusing on certain kinds of 
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drugs may result in lack of generalizability. LCA is a well-established methodology to 
identify subgroups with distinct behavior in a population. This technique has been 
applied to explore classes of drug use [42-48] and then to explore associations of each 
class with specific risk factors. 
Researchers using LCA analysis among MSM who use drugs have focused primarily on 
HIV infection and related risk factors. In these studies, classes of MSM who use drugs 
are between 2 to 6, such as low-risk (limited or negligible) drug use, recreational/club 
drug use, conventional drug use, street drug use, multiple drug use, etc. In one US 
internet-based MSM sample, a using sex-drugs group was more likely to engage in 
particular potentially high-risk sexual behaviors, and a distinct polydrug use group was 
identified. [49] Another US internet-based MSM sample showed that MSM who used 
polydrug were more likely to report unprotected anal intercourse, and sexual transmitted 
infection. [50] One US internet-based African American MSM sample identified 3 
classes: persons who used polydrug were more likely to report sex exchange, recent 
sexually transmitted infection compared to other classes, and persons who used alcohol 
and polydrug were more likely to report sex under the influence [51]. A young MSM 
sample from Chicago reporting high substance use rates were classified into 3 distinct 
groups (persons who used alcohol and marijuana, polydrug, and less marijuana) [52]. In 
a Malaysia Asia internet-based MSM sample, an ATS (amphetamine-type stimulant) 
class was more likely to have more than 6 male sex partners, have group sex, report 
inconsistent condom use, be HIV infected, and have a sexually transmitted infection 
compared to a low-risk drug use group [53]. Very few published literatures can be 
found, which applied LCA for classifying NIUD MSM and explored the association with 
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HCV infection and other risk factors. This study used LCA to identify subgroups of NIDU 
MSM and evaluate the relationship between drug use patterns and HCV infection. 
Social network analysis 
The science and techniques of network analysis have a great impact on the research on 
the dynamics of interacting elements. [54] The concept of “social network” was first 
introduced by J.A. Barnes in 1954 in the context of anthropology, representing social 
contact between individuals. [55] In 1985, this concept was first applied in Epidemiology 
on an HIV study to show the usefulness of a network approach to evaluate an infectious 
agent with unknown etiology and to develop strategies to reduce the transmission 
through personal contact. [56]  
The spread of an infectious disease naturally forms a transmission network, and this 
network underlies the person to person contact network. Especially for sexually 
transmitted disease, people are usually infected by their close network, not by a random 
person at large. By observing and analyzing the structure of contact network, we may 
get an insight into the epidemiological dynamics (understand and predict the spread of 
infection), and the knowledge of transmission route defined by network structure can be 
used as part of intervention and prevention. 
Social network models incorporate both individual attributes (socioeconomic status, 
age, race, weight, etc) and relationship between elements (kinship, friendship, sexual 
relationship, affiliated organizations, etc.), which may lead to or influence the infection of 
disease, whereas traditional infectious disease models are only based on individual 
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attributes and uniform-mixing assumption (assume the probability of person-to-person 
contacts are the same for each individual). 
Inspired by the first application of social network analysis on HIV/AIDS [56], more 
research has been conducted in the field of STDs by using sexual network or social 
network information, such as HIV [57-61], syphilis [62-64], gonorrhea [65], and 
chlamydia [66]. Very few published studies have used a social network approach to 
study sexually transmitted HCV. One study incorporated epidemiological and 
phylogeographical approaches indicating that some subtype of HCV was associated 
with younger people, possibly with higher rates of sexual transmission, suggesting 
social factors may play a key role in determining the rate and pattern of HCV 
transmission. [67] However, further study is needed in this field to further understand 
sexual transmission by using social network approach. 
This study explored HCV transmission factors by using a simple network structure -- 
dyads within egocentric networks.  This study analyzed the relationships between the 
character of dyadic links in a subset of egocentric networks of MSM and the likelihood 
that subjects are infected with HCV. According to Neaigus, dyads data may also yield 
useful results and is feasible among hidden populations such as MSM [68].   
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Knowledge gap 
Very few published studies have examined HCV infection among NIDU MSM, which 
could be a neglected subpopulation at risk of HCV infection. In addition, research on 
sexual transmission of HCV among heterosexual and homosexual couples has yielded 
mixed results. This proposed study would infer, although cannot confirm, sexual 
transmission evidence among the study populations. Furthermore, latent class analysis 
and social network analysis methods have been used for HIV related study among 
MSM, but seldom used for HCV study among MSM. This proposed study is attempting 
to use these approaches to evaluate and discuss HCV infection by using the subset of 
data from two NIH funded projects: Drugs, AIDS, STDs, and Hepatitis project (DASH, 
PI: Lu-Yu Hwang), and Young Men’s Affiliation Project (YMAP, PI: Kayo Fujimoto). 
 
Public Health Significance 
This study may provide a better understanding of HCV transmission among NIDU MSM. 
We will obtain the characteristics of the study populations associated with HCV 
infection. These results may provide a profile of subgroups with a higher HCV 
transmission possibility among NIDU MSM. In the long term, the results of the proposed 
study may guide the development of healthcare and behavior intervention programs 
related to HCV transmission, and may also guide tailored screening or treatment 
strategy on HCV infection. Therefore, the results of the study may help to reduce the 
subsequent burden of advanced liver diseases attributed to HCV in NIDU MSM, by 
slowing the incidence and decreasing the prevalence of HCV infection in this 
marginalized and underrepresented population. 
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Specific Aims and Hypothesis 
This proposed study will explore the risk factors of HCV infection in two study 
populations of NIDU MSM. The results will provide a profile of sub-population in MSM 
that susceptible to HCV infection, and provide some evidence of sexual transmission of 
HCV among NIDU MSM.  
Specific aim 1 
To determine risk factors associated with HCV infection among NIDU MSM in Houston, 
using a subset of data from Drugs, AIDS, STDs, and Hepatitis (DASH) project. 
Hypothesis: NIDU MSM who engage in risky sexual behaviors (unprotected anal 
intercourse, multiple sexual partners, trading sex, etc.) will be more likely to have HCV 
infection, compared to those who do not engage in these risk sexual behaviors. 
Specific aim 2 
To investigate subgroups of non-injection drug use among MSM using latent class 
analysis, and to evaluate the effect of these subgroups on HCV infection, using a subset 
of data from Drugs, AIDS, STDs, and Hepatitis (DASH) project. 
Hypothesis: NIDU MSM have distinct drug use subgroups, and these subgroups are 
different in the risk of HCV infection. Sex-related drug use will be associated with HCV 
infection. 
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Specific aim 3 
To examine relationships between dyadic links in a subset of egocentric networks of 
NIDU MSM, engagement in high-risk sex behaviors, and the likelihood that subjects are 
infected with HCV, using a subset of data from Young Men’s Affiliation Project (YMAP). 
Hypothesis: dyadic links and ego attributes related to high-risk sex behaviors, HIV 
infection and syphilis infection will be associated with HCV infection among young NIDU 
MSM. 
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PARENT STUDY: DASH PROJECT  
The data of the first and second studies came from the data of Drugs, AIDS, STDs, and 
Hepatitis (DASH) project.  
The DASH project was a community-based intervention study among non-treatment 
drug using population for HIV, HBV, and HCV prevention. The project screened 2800 
individuals who injection and non-injection drugs from February 2004 to October 2007 in 
two inner city neighborhood communities in Houston, Texas. Participants were recruited 
by using outreach and chain referral method. [20] Chain referral method is a sampling 
technique where a small pool of initial study subjects is used to recruit future subjects 
through their social networks. This sampling method is often used to reach hidden 
populations. This study was approved by the Committee for the Protection of Human 
Subjects at the University of Texas Health Science Center. 
The eligibility criteria for individuals included in the screening process were: 1) 18 years 
old or above, 2) self-reported living in Houston, 3) self-reported use of illegal and non-
medical prescribed drugs including cocaine or heroin in the last 48 hours and confirmed 
presence of drug metabolites by urinalysis (OnTrak Varian Testik, Palo Alto, CA.), 4) 
willing to sign the informed consent form for HIV, HBV, and HCV testing. Individuals 
with negative drug metabolites test were excluded from the study. 
Data collection  
Every individual completed an initial screening interview, which comprised a verbally 
administered questionnaire via computer-assisted personal interview (CAPI, QDS, 
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Bethesda, MD) to obtain the demographic information, history of drug use for drugs, 
sexual behaviors, history of sexually transmitted diseases, and blood transfusion and 
occupational exposure to blood.  
Separate from the screening interview, the baseline enrollment interview collected 
additional information on drug use, including frequency of drug use in past 30 days, a 
detailed history of binging for each of these drugs, experience in injection drug use.  
Laboratory methods 
All serum specimens obtained from screened individuals were tested for HIV1/2 
antibodies, HBsAg and HCV antibody infection using Core Combo HIV-HBsAg-HCV 
(Core Diagnostics, United Kingdom). Verification of HIV was conducted by enzyme 
immunoassay (EIA), using Abbott PPC Commander system, third generation HIV 
antibody test (Abbott Laboratories, Chicago, IL). Verification of HCV, anti-HBs, and anti-
HBc was conducted by Abbott AxSYM system, using microparticle enzyme 
immunoassay (MEIA) (Abbott Laboratories, Chicago, IL). 
Definition of HCV infection was the presence of antibody to HCV. HIV infection was 
defined as repeatedly reactive results by EIA. Case definition of HBV was the detection 
of anti-HBs or anti-HBc. 
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PARENT STUDY: YMAP PROJECT  
The material of the third study obtained from Young Men’s Affiliation Project (YMAP) in 
Houston, TX. 
YMAP is a longitudinal network study conducted from 2014 to 2017 to investigate social 
networks and attendance history at social venues and health-promoting venues among 
young MSM, and to determine how these networks affect HIV and sexually transmitted 
disease risk and prevention in Houston, TX and Chicago, IL. [62, 70-72] Respondents 
were included in this study if they identified as male sex assigned at birth and current 
male identification, were aged between 16-29 years old, reported oral or anal sex with 
another male in the past 12 months, were residing in and planning to remain in Houston 
for the following year, and were English-speaking. The study was approved by the 
institutional review boards at each location (HSC-SPH-12-0830). 
Data collection 
The sampling method in the YMAP study was Respondent Driven Sampling (RDS). [73] 
This method has been applied to recruit hard-to-reach populations such as MSM. The 
“seeds” were defined as respondents enrolled via representatives at health service 
providing facilities or at social venues. “Sprouts” were defined as respondents who were 
referred by “seeds”. Four vouchers were given to each participant to recruit other YMSM 
(sprouts) to produce chained samples.  
Interviews were conducted using a computer-based personal-interview combined with a 
computer-assisted self-interview delivered via Qualtrics (Qualtrics LLC, Provo, Utah). In 
the computer-assisted personal interviews, the trained data collector read questions 
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from the computer and entered data. Information were collected on demographic 
characteristics, drug use, social and sexual networks, and behavior with peers, and 
participants’ affiliation with community organizations and businesses. 
Laboratory methods 
After the interview, each participant provided biological blood specimen for HIV, HCV, 
and syphilis. HIV tests included fourth generation rapid test, using Alere Determine HIV-
1/2 Ab/Ag combo (Abbott Laboratories, Chicago, IL), viral load quantitative test, using 
Cobas AmpliPrep/Cobas TaqMan HIV-1 test kit, version 2,0 (Roche Molecular 
Diagnostics, Pleasanton, CA), and confirmatory test, using Geenius HIV -1/2 
Confirmatory test (Bio-rad, Marnes-la-Coquette, France). Tests for syphilis infection 
included rapid plasma regain (RPR) test, using Macro-Vue RPR Card test Kit (BD 
Diagnositics, Franklin Lakes, NJ), and fluorescent treponemal antibody FTA test, using 
Immunofluorence Assay FTA-Absorption Test System (Zeus Scientific, Branchburg, 
NJ). The test for HCV was HCV antibody rapid test (Boson Biotech, Xiamen, CN).  
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METHODS FOR SPECIFIC AIM 1 
Study design and study population 
This study was a cross-sectional study using a subset of screening data from DASH 
project, restricting to individuals who reported never having injected drugs and ever 
having male-to-male sex. Among 2800 individuals who were screened, 273 NIDU MSM 
were selected in this proposed study (Figure 1). 
Figure 1. Study population for specific aim 1 
Ascertainment of dependent and independent variables 
Dependent variable was HCV status, which is defined as the existence of HCV antibody 
or not. Independent variables were demographic measures such as age, race, living 
arrangement, jail history of more than 24 hours, and behavior measures such as 
number of sexual partners, frequency of condom use, trade sex for money or drugs, 
drug or alcohol use in past 7 days, number of drugs used in past 7 days, and biological 
measures such as HIV status, HBV status, history of sexually transmitted diseases. 
Screened in DASH
N=2800
IDU
N=961
NIDU
N=1839
NIDU
Not MSM
N=1566
NIDU MSM
N=273
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Power estimation 
Assuming a sample size of 284 participants and a two-sided test with 0.05 significant 
level, a minimal odds ratio was 1.7 to obtain a power of at least 80%, for overall HCV 
prevalence is 15.5% and assuming 5%-15% in unexposed group and 10%-30% in 
exposed group (Table 1). This power estimation was calculated by using OpenEpi 
software. [69] 
Table 1 Study power (1-𝛽) estimation given sample size of 273, significant level of 0.05 
and different HCV prevalence in exposed/unexposed groups for specific aim 1 
 
Statistical analysis 
Univariable analysis was conducted for each demographic characteristic, behavioral 
and biological variable. Number and percentage were calculated for categorical 
variables, while median and interquartile range (IQR) was computed for continuous 
variables. Then, Exact Logistic Regression was conducted for bivariable analysis to 
statistically test the association between the independent variables and HCV infections, 
and crude odds ratio (cOR) and 95% confidence interval with p-values were obtained. A 
final multivariable model was constructed by first using all variables significant at p<0.25 
in bivariable analysis as full model, then backward elimination was used to reach the 
final model. The statistical significance level was 5%. SAS 9.4 was used to manage and 
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analyze the data (Cary, NC). Hosmer-Lemeshow goodness of fit test was used to test 
the fit of the final model. 
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METHODS FOR SPECIFIC AIM 2 
Study design and study population 
This study was a cross-sectional study using a subset of baseline data from the DASH 
project, restricted to participants who reported male-to-male sex and never injected 
drugs. Among 2800 individuals who were screened, 1260 who were negative for HIV 
and HBV were enrolled for intervention to improve HBV vaccination adherence, and 
within the enrolled participants, 118 NIDU MSM were selected in this proposed study. 
(Figure 2) 
 
Figure 2. Study population for specific aim 2 
 
Screened
N=2800
Enrolled
N=1260
IDU
N=410
NIDU
N=850
Not MSM
N=732
MSM
N=118
Not enrolled
HIV (+) or HBV (+)
N=1540
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Measures 
For latent class analysis, indicators used for class identification included the use of the 
following drugs: crack cocaine, powder cocaine, methamphetamine, marijuana, alcohol, 
and heroin.  
For multi-nominal logistic regression, the dependent variable was the class of persons 
who used drugs classified by latent class analysis (e.g. class 1 vs 2, class 2 vs 3 and 
class 1 vs 3) (see statistical analysis below). The independent variable comprised 
demographic measures (such as age, race/ethnicity, education level, living 
arrangement, jail history of more than 24 hours), risk behavior variables (such as 
number of sexual partners in the past 30 days, sexual orientation, condom use, trading 
sex for money or drugs in past 30 days), HCV status, sexually transmitted diseases 
histories.  
For multivariable logistic regression, the dependent variable was HCV status. 
Independent variables were demographic measures (such as age, race/ethnicity, 
education level, living arrangement, hail history of more than 24 hours), risk behavior 
variables (such as number of sexual partners in the past 30 days, sexual orientation, 
condom use, trading sex for money or drugs in past 30 days), sexually transmitted 
diseases history, and classes of drug use (drug use subgroups defined by latent class 
analysis).  
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Power estimation 
For latent class analysis no formal approach has been taken so far; however, several 
useful statistics were used to evaluate the fitting of the model. 
For logistic regression, assuming a sample size of 110 participants and a two-sided test 
with 0.05 significant level, a minimal detectable odds ratio was 3.8 to obtain a power of 
at least 80%, for overall HCV prevalence is 17% and assuming 5%-15% in unexposed 
group and 20%-35% in exposed group (Table 2). This power estimation was calculated 
by using OpenEpi software. [69] 
Table 2 Study power (1-𝛽) estimation given sample size of 118, significant level of 0.05 
and different HCV prevalence in exposed/unexposed groups for specific aim 2. 
  
Statistical analysis 
Descriptive statistics was used to demonstrate the characteristics of the study sample. 
Latent class analysis was used to examine the subgroups of drug use (Figure 3). Drug 
use indicator variables were used in the LCA model. Starting with a one class model 
and increasing the number of classes, a series maxima were reached. Multiple model fit 
statistics were used to determine the best-fitting, most parsimonious model, including 
the chi-square value, Bayesian information criteria (BIC), LMR and so on. 
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Figure 3. Latent class model of drug use among MSM with covariate predictors 
* The reply for the question: “Have you ever uesd this drug?” 
After deciding on the appropriate number of classes that best fit the data, multi-nominal 
logistic regression was used to explore the characteristics of drug use subgroups and 
the association between classes (different subgroups of drug use) and demographical, 
behavioral, HCV status variables. A final multivariable model was constructed by first 
using all variables significant at p<0.25 in bivariable analysis as full model, then 
backward elimination was used to reach the final model. In addition, multivariable 
logistic regression was used to examine characteristics of individual associated with 
HCV infection, controlling for drug use subgroups. A final multivariable model was 
constructed by first using all variables significant at p<0.25 in bivariable analysis as full 
model, then backward elimination was used to reach the final model. 
The statistical significance level was 5%. Mplus 6.1 (Muthén & Muthén, CA) was used 
to conduct the LCA model building. SAS 9.4 (Cary, NC) was used to manage the data 
and build multi-nominal and multivariable logistic regression.  
*Crack 
Cocaine
Powder 
cocaine
Meth
Mariju-
ana
alcohol Heroin other
Drug use 
latent 
classes
Covariate predictors:
Demographics
Sex Behaviors
STDs
HCV
Figure 3. Latent class model of drug use among MSM with covariate predictors.
* For each drug use, the indicator variable will include two variables:
1) The frequency of drug use in the past 30 days:
0=never use, 
1=ever use but not used in the past 30 days, 
2=less than 5 times, 
3=5-29 times, 
4=30 times or more.
2) The duration of drug use (in y ars).
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METHODS FOR SPECIFIC AIM 3 
Study design and study population 
This study was a cross-sectional network study. The study sample was a subset of 
YMAP baseline data restricted to participants who report never having injected drugs, 
collected from December 2014 to December 2015 in Houston. A total of 366 
participants in YMAP were selected into this study.
 
Figure 4. Study population for specific aim 3 
  
Measures 
Dependent variable was HCV status, which was defined as the existence of HCV 
antibody or not. 
Independent variables included two sets, respondent’s measures and sexual network 
dyad measures. For respondent’s measures, demographic information (such as age, 
YMAP HOUSTON
YMSM
N=378
Never used drugs
n=5
DU MSM
n=369
NIDU
n=366
IDU
n=3
Drug use info is 
missing
n=4
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race, education level, living arrangement, and jail history for more than 24 hours) was 
used. For sexual network dyad measures, all these data were treated as clustered data 
on respondent, including sexual ties (determined by asking respondents to nominate up 
to five people with whom they had sex within the past six months), and their behavioral 
measures (such as main/casual relationship, frequency of condom use, whether used 
drugs before sex, HIV status of both respondent and sex partner, and syphilis status of 
both respondent and sex partner). 
Statistical analysis 
The unit of analysis was the dyad, which was the pair of respondent and his nominated 
sexual partner.  
Chi-square test was used to assess the relationship between baseline respondents' and 
their sexual partners’ characteristics, such as age, race/ethnicity, sexual orientation, and 
HIV status. 
Homophily was defined of the following variable, age homophily (evaluated by the 
absolute value of age difference between a respondent and his nominated sex partner), 
race/ethnicity homophily (evaluated by dichotomy scale: same/discordant), HIV 
serostatus homophily (evaluated as 1= respondent HIV seropositivity and respondent’s 
perception about sex partner’s positivity, 2=respondent HIV seropositive and 
respondent’s perception about sex partner negative, 3=respondent HIV seropositivity 
and respondent’s perception about sex partner’s unknown, 4=respondent HIV 
seronegative and respondent’s perception about sex partner positive, 5=respondent HIV 
seronegative and respondent’s perception about sex partner negative, 6=respondent 
 30 
HIV seronegative and respondent’s perception about sex partner unknown). 
Generalized Estimating Equations model (GEE) model, which can justify cluster 
observation of respondents [74] was used to conduct bivariate and multivariable 
analysis. Bivariate analyses were conducted between HCV status and each 
independent variable using crude odds ratio (cOR) and 95% confidence intervals. 
Multivariable GEE model was conducted to statistically test if there is an association 
between HCV infection status and the dyadic network measures. The statistical 
significance level was 5%. SAS 9.4 (Cary, NC) was used to manage the data and 
conduct the GEE analysis. 
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JOURNAL ARTICLE 
Article I: Hepatitis C infection and its associated risk factors in men who have sex 
with men who reported non-injection use of drugs 
This article has been formatted for the Journal of Viral Hepatitis  
 
ABSTRACT 
Background: Hepatitis C virus infection is more prevalent among high risk populations 
in the U.S. We assessed risk factors for HCV infection among men who have sex with 
men (MSM) who acknowledged drug use but not injection drug use.  Methods: The 
DASH project, a community-based study in Houston, Texas, collected data from people 
who reported injection or non-injection use of drugs (drug use was defined as self-
reported use of marijuana, alcohol, methamphetamines, cocaine, heroin, uppers, 
downers in the past 7 days and confirmed by urine test) collected in 2004-2007. Our 
analysis focused on the MSM who reported drug use but no injection drug use. Exact 
logistic regression was used to determine demographic characteristics, sexual risk 
behaviors and sexually transmitted disease history associated with HCV infection. 
Results: Among 273 MSM, the HCV prevalence was 14.7%. Only age was significantly 
associated with HCV infection. Compared to participants aged 19-41, those aged 42-74 
had 2.1 times the odds of having HCV infection (95%CI: 1.4-3.0). HIV status and sexual 
risk behaviors such as unprotected intercourse, multiple sex partners, and trading sex 
for money or drugs were not significantly associated with increased HCV infection. 
Conclusion: MSM ages 42 years old and above were at greater risk for HCV infection 
than other age groups among MSM who reported drug use but no injection drug use.  
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Sexual risk behaviors were not identified as a risk factor of HCV infection. We call for 
health education about HCV infection to increase awareness of HCV testing and 
treatment in this subpopulation of MSM who reported drug use but no injection drug 
use. 
INTRODUCTION 
Hepatitis C virus (HCV) infection affects primarily the liver and causes acute and chronic 
hepatitis with a high propensity for chronicity[1]. It is the leading cause of cirrhosis, 
hepatocellular carcinoma, and liver transplantation in the United States[2]. In the United 
States, it is estimated that 3.5 million people are living with HCV infection, which 
accounts for about 1% of the population[3]. Studies shows the HCV prevalence is 
higher in some risk populations such as people who use drugs [4, 5] and HIV-positive 
men who have sex with men (MSM) [6]. HCV prevalence among IDU is reported as 
70% and among NIDU 17.9%. [7] HCV prevalence among IDU is reported as 70% and 
among NIDU 17.9%. [7] However, the rate of access to diagnosis and treatment is low; 
of the people living with HCV globally, 20% knew their diagnosis, and only 7.4% of the 
diagnosed were started on treatment [8]. In addition, current treatment rates and 
efficacy are inadequate to manage the disease burden caused by HCV [9]; thus, efforts 
are needed to reduce HCV transmission.  
Besides health-care-associated transmission and transmission through injecting drugs, 
other transmission routes, such as sexual transmission, sharing equipment of non-
injection drug use, are not conclusive. HCV was found to be transmitted by sexual 
contact, especially among HIV-positive MSM [10-14], but for HIV-negative MSM, sexual 
contact might not increase the risk of HCV infection [15, 16]. Transmission by sharing 
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drug use equipment for non-injection drug use has also been reported but with mixed 
results [17-22]. One systematic review, however, reported that the HCV prevalence 
ranged from 2.3% to 35.3% in the population who reported drug use but no injection 
drug use and was higher than the prevalence in the population who did not use 
drugs[5].  
For MSM and drug-using behavior, MSM were found to have a higher drug use 
prevalence than in the general population [23, 24], which might contribute to HCV 
infection by sexual disinhibition and other risky behaviors. One systematic review and 
meta-analysis, which targeted only HIV-positive MSM, reported that the pooled HCV 
prevalence was 6.7% among NIDU, and the prevalence was increasing over time [6]. 
Previous studies on risk factors associated with HCV infection focused mainly on HIV-
positive MSM and/or MSM who reported injection drug use, so studies are needed that 
target MSM who reported drug use but no injection drug use. This study estimated HCV 
prevalence and examined risk factors associated with HCV infection among MSM who 
reported drug use but no injection drug use in Houston, TX. The hypothesis of this study 
was that sexual risk behaviors were significantly associated with HCV infection in MSM 
who reported drug use but no injection drug use. These results may provide a profile of 
subgroups with a higher HCV transmission possibility among MSM who reported drug 
use but no injection drug use. In the long term, the results of the study may guide the 
development of healthcare and behavior intervention programs related to HCV infection, 
providing better informed and more effective HCV prevention. 
METHODS 
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Study set and participant sampling 
Data were obtained from the Drugs, AIDS, STDs and Hepatitis (DASH) project, which 
was a community-based intervention study for HIV, HBV, and HCV prevention among a 
drug-using population [25]. The project screened 2,800 individuals with injection and 
non-injection use of drugs from February 2004 to October 2007 in two inner-city 
neighborhood communities in Houston, TX. Participants were recruited by using 
outreach and chain referral method. The eligibility criteria included in the screening 
process were: (1) 18 years old or above; (2) self-reported living in Houston; (3) self-
reported use of illegal and non-medical prescribed drugs, including cocaine or heroin in 
the last 48 hours and confirmed presence of drug metabolites by urinalysis (OnTrak 
Varian Testik, Palo Alto, CA.); (4) willingness to sign the informed consent form for HIV, 
HBV, and HCV testing.  
Data collection 
Every  individual completed an initial screening interview, which constituted a verbally 
administered questionnaire via computer-assisted personal interview (CAPI, QDS, 
Bethesda, MD) to obtain socio-demographic information (such as age, gender, 
race/ethnicity, sexual orientation, living arrangement, and jail history of more than 24 
hours); history of drug use for drugs including marijuana, alcohol, methamphetamine, 
heroin, cocaine, uppers and downers (such as types and frequency of drugs used in the 
past 48 hours and 7 days, and lifetime injection drug use); sexual behaviors (such as 
number of sexual partners in the past 30 days, frequency of condom use, and trading 
sex for money or drugs in past 30 days); history of sexually transmitted diseases (such 
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as gonorrhea, herpes, chlamydia, and trichomoniasis); blood transfusion and 
occupational exposure to blood.  
All serum specimens obtained from screened individuals were tested for HIV1/2 
antibodies, HBsAg and HCV antibody infection using Core Combo HIV-HBsAg-HCV 
(Core Diagnostics, United Kingdom). Verification of HIV was conducted by enzyme 
immunoassay (EIA), using Abbott PPC Commander system, third generation HIV 
antibody test (Abbott Laboratories, Chicago, IL). Verification of HCV, anti-HBs, and anti-
HBc was conducted by Abbott AxSYM system, using microparticle enzyme 
immunoassay (MEIA) (Abbott Laboratories, Chicago, IL). 
Definition of HCV infection was the presence of antibody to HCV. HIV infection was 
defined as repeatedly reactive results by EIA. Case definition of HBV was the detection 
of anti-HBs or HBsAg or anti-HBc. 
Statistical analysis 
Univariable analyses were conducted for each socio-demographic characteristic, sexual 
risk behavioral and biological variable. Numbers and percentages were calculated for 
categorical variables, while medians and interquartile ranges (IQR) were computed for 
continuous variables. Chi-square or Fisher exact tests were used to test the difference 
of HCV status among different categories of each independent variable. Then, exact 
logistic regression analyses were performed for bivariable analysis to statistically test 
the association between each independent variable and HCV status, and odds ratio 
(cOR) and 95% confidence interval with p-values were obtained. Interaction terms were 
evaluated in the model. The statistical significance level was set at 5%. Hosmer-
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Lemeshow goodness of fit test was used to test the fit of the final model. SAS 9.4 was 
used to manage and analyze the data (Cary, NC).  
RESULTS 
There were 273 MSM who reported drug use but no injection drug use in this study; of 
these, 14.7% were infected with HCV (Table 1). Age of the sample ranged from 19 to 74 
years old, with the mean age of 39.6 years old (IQR: 35-46), 85% were African 
American, 61% were homeless at least once, 25% were currently living on the street, 
and 66% reported their sexual orientation as bisexual. About one third of the 
participants had traded sex for money, half had traded sex for drugs, and one third 
never used condoms while having sex. A total of 77% had been in jail, 49% had been 
diagnosed with a sexual transmitted disease, and 19% were HIV positive. The majority 
of the study participants had used crack cocaine (98%), alcohol (83%) and marijuana 
(58%) in the last 7 days. The demographic, socio-behavioral, and 7-day drug use 
profiles stratified by HCV status are presented in table 1.  
Of the demographic, socio-behavioral, and drug use variables, only age was observed 
to have significant association with HCV status. Compared to the 19-41 year age group 
(HCV prevalence 7.1%), and the 42-74 year age group (24.6%) had more than 2 times 
the odds of having HCV infection (OR = 2.1, 95%CI: 1.4-3.0) (Table 2).  
Being Caucasian, currently homeless, of straight sexual orientation, having a blood 
transfusion history, occupational blood exposure history, or being HIV positive was 
associated with increased HCV infection, but none of these associations were 
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statistically significant at the 5% level. No significant difference in HCV infection was 
discovered in any kind of drug use in the last 7 days. 
Interaction terms were examined in the multivariable model, but none of them were 
significant at the 5% level. Only age was retained in the multivariable logistic regression 
model after backward selection. Also, the association between age and HCV infection 
did not change more than or equal to 15% when any other variables were entered in the 
model. The final model included only age as a predictor of HCV infection.  
DISCUSSION 
We found that the overall HCV prevalence in MSM who reported drug use but no 
injection drug use was relatively high, and only age was significantly associated with 
HCV infection, specifically among MSM ages 42 years old and above, who had the 
highest risk of HCV infection compared with the younger age group. In addition, sexual 
risk behavior and HIV infection were not significantly associated with HCV infection. 
Overall, the HCV prevalence was 14.7% in these MSM who reported drug use but no 
injection drug use. The result was comparable to an average of 14.0% HCV infection in 
the general population who reported non-injection drug use, reported in a systematic 
review of 28 studies [5], but higher than the HCV prevalence in the general MSM 
population (2.8%), reported in a large community-based study in New York [27]. The 
prevalence was also higher than that among HIV-positive MSM (8.1%), described in a 
systematic review and meta-analysis of 42 studies [28]. These comparisons may 
suggest that, although it could not be explicitly determined, the behavior of non-injection 
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drug use outweighed the behavior of MSM with regard to HCV infection among these 
MSM who reported drug use but no injection drug use. 
Age was the only factor that was significantly associated with HCV infection. Among 
MSM ages 45 years and older, the HCV prevalence was 27%, 8 times more likely to 
have HCV infection than the youngest age group (19-35 years old). This result was 
consistent with previous studies which demonstrated people born during 1945-1965, 
known as baby boomers, had the highest possibility of HCV infection compared with 
other generations [29]. Moreover, the baby boomers in our study had much higher HCV 
prevalence than general baby boomers, whose HCV prevalence was estimated to be 
3.3% [30], indicating a high HCV disease burden in the subpopulation of the baby 
boomer generation who are MSM and report drug use but no injection drug use. 
For the possible transmission route of HCV, our study findings did not support our 
hypothesis that sexual risk behaviors, including unprotected intercourse, multiple sex 
partners, and trading sex for money or drugs, significantly increased the risk of HCV 
infection. This result was consistent with that Joy et al. [31] who suggest the reuse of 
glass and metal syringes in medical practice dating back to 1940 to 1960 was 
associated with the highest expansion of HCV infection in the generation of baby 
boomer. Importantly, Joy et al. used molecular-clock approaches and reconstructed the 
epidemiology of HCV in North America, destigmatizing the baby boomers with 
nosocomial activity as the main contributor to HCV epidemic in North America, rather 
than risky sex and injection drug use behavior [31].  
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It is worth noting that HIV infection did not significantly increase the risk of HCV 
infection, which contrasts with the increasing reports of an HCV epidemic or outbreak in 
HIV-positive MSM in Europe, Australia, and North America since 2000 [10-14]. The 
possible reason was that the HCV infection rate was also high in HIV-negative 
participants in the present study, which raised the bar that detected the effect of HIV co-
infection on promoting HCV transmission in this study. Another possible reason was 
that the HIV and HCV epidemics have unrelated transmission dynamics in this 
population, which was also reported in one study in Hong Kong [32]. To confirm the 
transmission dynamics, investigation of social and sexual networks combined with 
phylogenetic approaches may help unveil the transmission pattern of the two viruses. 
Regarding types of drug use, none of them showed association with HCV infection. The 
reason was likely that only the last 7-day drug use information was collected in this 
screening investigation, which may not relate to chronic HCV infection. Information on 
detailed drug use history may help explain the relationship between drug use types and 
HCV infection. In addition, increased risk of HCV infection related to sharing implements 
for smoking or snorting drugs, as well as sharing non-injection drugs, should be 
evaluated, although some studies show no association between sharing implements or 
non-injection drugs with HCV infection [17-20], other studies have reported opposite 
results [21, 22]. 
Strengths of the study, besides the relatively large sample size, include that HCV and 
HIV status were confirmed by laboratory test in this project, not self-report, which greatly 
reduced misclassification. In addition, the use of drugs was confirmed by urine test, not 
self-report, which reduced information bias. However, there were several limitations in 
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this study. First, information collected in these screening data did not include some 
specific kinds of drug preferred by MSM in recent years, for example, sex/club drugs 
(ketamine, MDMA, LSD, and erectile dysfunction drugs). In addition, several sexual risk 
behaviors specific to MSM were not examined, such as frequency of receptive anal 
intercourse, or experience of mucosal trauma during sex. Furthermore, as mentioned 
above, sharing equipment for non-injection drug use was not investigated in this study, 
which might also be a transmission path of HCV infection. Last but not least, most of the 
participants were African American, which limited the generalizability of the results in 
this study to other racial/ethnic populations. Further study is warranted specifically 
among MSM who report drug use but no injection drug use, with greater racial/ethnic 
diversity, to more fully examine risk factors related to HCV infection. 
In conclusion, individuals aged 45 years old and above had the highest risk of HCV 
infection among MSM who reported drug use but no injection drug use; sexual risk 
behaviors were not identified as a risk factor of HCV infection. For the baby boomer 
generation, the HCV testing rate was very low (<14%) [33]. Two factors, non-injection 
drug use and male-to-male sexual behavior, may marginalize this subpopulation in the 
baby boomer generation, possibly leading to an even lower testing rate. Health 
education should be promoted in this subgroup to enhance the awareness of HCV 
infection and increase HCV testing rates. We also call for regulating HCV testing in 
medical systems that care for this subpopulation, and for the promotion of treatment in 
HCV infected individuals to attenuate the disease burden. 
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Table 1 Characteristics and HCV infection among MSM who reported drug use but no 
injection drug use in two inner city communities in Houston, TX (N=273) 
Characteristics Total HCV+ HCV- Chi-square 
P-value 
Age (year)       <0.001 
    19-41 155 (56.8) 11 (7.1) 144 (92.9)   
    42-74 118 (43.2) 29 (24.6) 89 (75.4)   
Race       0.478* 
    Caucasian 34 (12.5) 7 (20.6) 27 (79.4)   
    Hispanic 8 (2.9) 1 (12.5) 7 (87.5)   
    African American 231 (84.6) 32 (13.9) 199 (86.1)   
Homeless       0.643 
    Yes 107 (39.2) 17 (15.9) 90 (84.1)   
    No 166 (60.8) 23 (13.9) 143 (86.1)   
Homeless (currently live on street)       0.229 
    Yes 68 (24.9) 13 (19.1) 55 (80.9)   
    No 205 (75.1) 27 (13.2) 178 (86.8)   
Frequency of using condom       0.433 
    None 97 (35.5) 15 (15.5) 82 (84.5)   
    Some 143 (52.4) 18 (12.6) 125 (87.4)   
    All 33 (12.1) 7 (21.2) 26 (78.8)   
Self-considered sex orientation       0.125 
    Gay 49 (17.9) 3 (6.1) 46 (93.9)   
    Straight 44 (16.1) 9 (20.5) 35 (79.5)   
    Bisexual 180 (65.9) 28 (15.6) 152 (84.4)   
No. of sex partners in past 4 weeks    0.139 
    0 57 (20.9) 11 (19.3) 46 (80.7)  
    1-4 109 (40.0) 19 (17.4) 90 (82.6)  
    >5 106 (38.8) 10 (9.4) 96 (90.6)  
Trade sex for money       0.133 
    Yes 99 (36.3) 9 (9.1) 90 (90.9)   
    No 56 (20.5) 9 (16.1) 47 (83.9)   
Unknown 118 (43.2) 22 (18.6) 96 (81.4)   
Trade sex for drug       0.217 
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Characteristics Total HCV+ HCV- Chi-square 
P-value 
    Yes 137 (50.2) 15 (10.9) 122 (89.1)   
    No 107 (39.2) 20 (18.7) 87 (81.3)   
    Unknown 29 (10.6) 5 (17.2) 24 (82.8)   
Blood transfusion       0.462* 
    Yes 14 (5.1) 3 (21.4) 11 (78.6)   
    No 259 (94.9) 37 (14.3) 222 (85.7)   
Occupational exposure       0.285* 
    Yes 17 (6.2) 4 (23.5) 13 (76.5)   
    No 256 (93.8) 36 (14.1) 220 (85.9)   
Ever in jail for 24 hours or more       0.973 
    Yes 211 (77.3) 31 (14.7) 180 (85.3)   
    No 62 (22.7) 9 (14.5) 53 (85.5)   
Diagnosed sexual transmitted diseases       0.541 
    Yes 86 (31.5) 12 (14.0) 74 (86.0)   
    No 91 (33.3) 11 (12.1) 80 (87.9)   
    Unknown 96 (35.2) 17 (17.7) 79 (82.3)   
Diagnosed syphilis ever       0.877 
    Yes 32 (18.1) 5 (15.6) 27 (84.4)   
    No 54 (30.5) 7 (13.0) 47 (87.0)   
    Unknown 91 (51.4) 11 (12.1) 80 (87.9)   
HIV status**       0.565 
    Yes 52 (19.2) 9 (17.3) 43 (82.7)   
    No 219 (80.8) 31 (14.2) 188 (85.8)   
Alcohol       0.614 
    Yes 226 (82.8) 32 (14.2) 194 (85.8)   
    No 47 (17.2) 8 (17.0) 39 (83.0)   
Marijuana       0.958 
    Yes 158 (57.9) 23 (14.6) 135 (85.4)   
    No 115 (42.1) 17 (14.8) 98 (85.2)   
Methamphetamines       0.594* 
    Yes 11 (4.0) 1 (9.1) 10 (90.9)   
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Characteristics Total HCV+ HCV- Chi-square 
P-value 
    No 262 (96.0) 39 (14.9) 223 (85.1)   
Cocaine       0.733* 
    Yes 268 (98.2) 39 (14.6) 229 (85.4)   
    No 5 (1.8) 1 (20.0) 4 (80.0)   
Heroin       0.182* 
    Yes 10 (3.7) 0  10 (100.0)   
    No 263 (96.3) 40 (15.2) 223 (84.8)   
Uppers       NA 
    No 273 (100.0) 40 (14.7) 233 (85.3)   
Downers**       0.471* 
    Yes 3 (1.1) 1 (33.3) 2 (66.7)   
    No 269 (98.5) 39 (14.5) 230 (85.5)   
* Fisher exact test P-value 
** Missing value: HIV status n=2, Downers n=1 
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Table 2 Results of univariable exact logistic regression of factors associated with HCV 
infection among MSM who reported drug use but no injection drug use in two inner-city 
communities in Houston, TX (n=273) 
Characteristics OR (95% CI) P-value 
Age (year)   
 
    42-74 2.1 (1.4-3.0)  <0.001 
    19-41 Reference   
Race   
 
    Caucasian 1.4 (0.6-3.3) 0.930 
    Hispanic 1.5 (NA) 0.776 
    African American Reference   
Homeless     
    Yes 1.1 (0.8-1.5) 0.767 
    No Reference   
Homeless (currently live on street)     
    Yes 1.2 (0.9-1.8) 0.315 
    No Reference   
Frequency of using condom   
 
    None 0.9 (0.6-1.5) 1.000 
    Some 0.7 (0.5-1.2) 0.355 
    All Reference   
Self-considered sex orientation     
    Gay 0.4 (0.2-1.0) 0.094 
    Straight 1.7 (0.9-3.2) 0.215 
    Bisexual Reference   
No. of sex partners in past 4 weeks   
    1-4 1.2 (0.8-1.9) 0.649 
    >5 0.6 (0.4-1.0) 0.085 
    0 Reference  
Trade sex for money   
 
    Yes 0.6 (0.4-1.0) 0.124 
    Unknown 1.4 (0.9-2.2) 0.280 
    No Reference   
Trade sex for drug     
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Characteristics OR (95% CI) P-value 
    Yes 0.7 (0.4-1.1) 0.238 
    Unknown 1.1 (0.6-2.3) 1.000 
    No Reference   
Blood transfusion     
    Yes 1.3 (0.7-2.5) 0.674 
    No Reference   
Occupational exposure     
    Yes 1.4 (0.8-2.5) 0.452 
    No Reference   
Ever in jail for 24 hours or more     
    Yes 1.0 (0.7-1.5) 1.000 
    No Reference   
Diagnosed sexual transmitted diseases     
    Yes 1.0 (0.6-1.6) 1.000 
    Unknown 1.3 (0.8-2.0) 0.507 
    No Reference   
Diagnosed syphilis ever     
    Yes 1.2 (0.6-2.4) 1.000 
    Unknown 0.9 (0.5-1.5) 0.953 
    No Reference   
HIV status     
    Yes 1.1 (0.8-1.7) 0.700 
    No Reference   
Alcohol     
    Yes 0.9 (0.6-1.4) 0.756 
    No Reference   
Marijuana     
    Yes 1.0 (0.7-1.4) 1.000 
    No Reference   
Methamphetamines     
    Yes 0.8 (0.3-2.1) 1.000 
    No Reference   
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Characteristics OR (95% CI) P-value 
Cocaine     
    Yes 0.8 (0.3-2.5) 1.000 
    No Reference   
Heroin     
    Yes 0.6 (NA) 0.199 
    No Reference   
Uppers     
    No 0.6 (NA) 0.199 
Downers     
    Yes 1.7 (0.5-5.7) 0.761 
    No Reference 
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Article II: The association between non-injection drug use and hepatitis C 
infection among HIV-negative men who have sex with men 
This article has been formatted for the Journal of Addictive Behaviors Reports 
 
ABSTRACT 
Objectives: This study investigated the association between drug use latent class and 
Hepatitis C Virus (HCV) infection in HIV-negative men who have sex with men (MSM) 
who reported drug use but not injection drug use. Methods: This cross-sectional study 
analyzed the data of 118 HIV-negative MSM who reported drug use but not injection 
drug use recruited from two inner-city communities between 2004 and 2007. Latent 
class analysis (LCA) was used to identify drug use latent classes. Multinomial logistic 
regression analysis was used to evaluate the association between drug use latent class 
and HCV infection. Results: Four distinct latent classes of drug use were identified: (1) 
persons >=42 years old who used only crack cocaine, (2) persons about 42 years old 
who used >2 drugs, (3) persons <42 years old who used >5 drugs, and (4) persons 
>=42 years old who used >6 drugs. Class 4, persons >= 42 years old who used >6 
drugs were significantly associated with HCV infection. Compared with persons about 
42 years old who used >2 drugs, persons >=42 years old who used >6 drugs had more 
than 16 times the odds of having HCV infection (adjusted OR = 16.9, 95%CI: 1.4-
205.4), and compared with persons <42 years old who used >5 drugs, persons >=42 
years old who used >6 drugs were about 22 times as likely to have HCV infection 
(adjusted OR=21.8, 95%CI: 1.5-322.8). Conclusions: The subgroup of MSM >=42 
years old with non-injection but multiple use of heroin, speedball, and 
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methamphetamine, in addition to crack cocaine and marijuana, had high probability of 
HCV infection. Public health and education programs, as well as drug treatment and 
rehabilitation programs, should be developed for this high-risk subgroup to prevent HCV 
acquisition and transmission. 
 
 
INTRODUCTION 
Compared with the general population, men who have sex with men (MSM) are 
disproportionately affected by infectious diseases, such as HIV, syphilis and other 
sexually transmitted infections (STI) (CDC, 2017). MSM may also be disproportionately 
affected by HCV.  HCV infection, which is a leading cause of liver failure and 
transplantation in the United States (Razavi et al., 2013), has been relatively 
understudied in MSM until 2000, when reports of an HCV epidemic or outbreaks in 
MSM began to emerge (Bottieau, Apers, Van Esbroeck, Vandenbruaene, & Florence, 
2010; Giraudon et al., 2008; Urbanus, van de Laar, et al., 2009; Urbanus, van Houdt, 
van de Laar, & Coutinho, 2009; van de Laar et al., 2007; Wandeler et al., 2012). Most of 
these studies focused on MSM who are HIV positive, MSM who inject drugs, or both. 
Studies targeting HIV-negative and non-injection drug using MSM are needed. 
Although HCV prevalence rates are comparable in HIV-negative MSM and in the 
general U.S. population (Blaxhult, Samuelson, Ask, & Hökeberg, 2014; Price et al., 
2013), people who use drugs but do not inject drugs have been found to have a higher 
HCV infection rate (2.3% to 35.3%) than in the general population (1%) (Scheinmann et 
al., 2007). Furthermore, MSM have been reported with a higher rate of drug use than in 
 52 
heterosexual men (past month prevalence 16.3% vs 9.9%) (Cochran, Ackerman, Mays, 
& Ross, 2004). These results showed a higher HCV infection rate in HIV-negative MSM 
with non-injection drug use than in the general population.  
People who use drugs are usually heterogeneous with regard to drug types, because 
drug types are various and one individual may choose multiple drug types at the same 
time or different times. Analyzing types of drug use independently may overlook the 
complexity of multiple drug use or result in lack of generalizability. To analyze the drug 
use variables simultaneously, we applied latent class analysis to identify subgroups of 
drug use (Carlson, Wang, Falck, & Siegal, 2005; Kuramoto, Bohnert, & Latkin, 2011; 
Monga et al., 2007; Sherman et al., 2009; Wittchen et al., 2009), and further explored 
the association between drug use subgroups and disease. In one US internet-based 
MSM sample, a distinct multiple drug use group was identified (McCarty-Caplan, Jantz, 
& Swartz, 2014). Another study recruited a similar sample of MSM and found that high 
multiple drug using MSM were more likely to report unprotected anal intercourse, and 
STIs (Yu, Wall, Chiasson, & Hirshfield, 2015). In a Malaysia Asia internet-based MSM 
sample, an amphetamine-type stimulant class was associated with sexual risk behavior 
and the infection of HIV and STIs, compared to a low-risk drug use group (Lim et al., 
2015).  
To the best of our knowledge, there are no studies of HCV infection targeting HIV-
negative MSM with non-injection drug use. To fill this knowledge gap, this study applied 
LCA to identify latent classes among MSM who reported drug use not no injection drug 
use, and examined the association between latent classes and HCV infection in HIV-
negative MSM. It was hypothesized that, first, there are distinct latent classes in the 
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target population, and, second, one or more latent classes are associated with HCV 
infection. The results of this study may provide insight for HCV prevention and health 
education programs targeted at HIV-negative MSM with non-injection drug use. 
 
METHODS 
Samples from DASH project  
Data for the present study were collected from a cohort of people who used drugs 
enrolled in the Drugs, AIDS, STDs, and Hepatitis (DASH) project, a community-based 
intervention study among a non-treatment drug-using population for HIV, HBV, and 
HCV prevention (Hwang et al., 2010). The DASH project recruited individuals from two 
highly endemic drug-using urban neighborhoods in Houston, TX, from February 2004 to 
October 2007. Participants were recruited by outreach workers using a chain referral 
approach. People were eligible for the study if they were: 18 years old or above, had 
local residence, self-reported use of illegal and non-medical prescribed drugs including 
cocaine or heroin in the last 48 hours and confirmed presence of drug metabolites by 
urinalysis (OnTrak Varian Testik, Palo Alto, CA.), and willingness to sign the informed 
consent form for HIV, HBV, and HCV testing.  
Individuals with negative HIV and HBV screening tests were enrolled into the baseline 
study. Enrollment interviews were conducted using verbally administered questionnaires 
via computer-assisted personal interview method (CAPI, QDS, Bethesda, MD). Baseline 
data were from the enrollment interview. All data collection procedures and laboratory 
protocols were approved by the Committee for the Protection of Human Subjects at the 
University of Texas Health Science Center at Houston. 
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Data for this study were restricted to 118 participants who reported male-to-male sex 
and did not report any injection drug use. (See DASH study population flow chart figure 
1) 
Measures 
For sociodemographic characteristics, information was collected on age, race/ethnicity, 
sexual orientation, education level, marital status, working status, income level, living 
arrangement, jail history of more than 24 hours, and drug treatment history. Sexual 
behavior variables included number of male sexual partners in the past 30 days, 
frequency of condom use, trading sex for money or drugs in the past 30 days, and 
trading money or drugs for sex in the past 30 days. Disease status comprised self-
reported STI history for gonorrhea, herpes, chlamydia, and trichomoniasis, as well as 
HCV infection status, screened by HIV1/2 antibodies, HBsAg and HCV antibody Combo 
test (Core Diagnostics, United Kingdom), confirmed by Microparticle enzyme 
immunoassay test (Abbott Laboratories, Chicago, IL). HCV infection was defined as 
HCV antibody positive. Also, history of blood transfusion, and occupational exposure to 
blood was collected during the enrollment interview. 
Drug use variables and age were used as latent class indicators. Drug use variables 
included the participants’ response to the question, “Have you ever used the following 
drugs: crack cocaine, methamphetamine, marijuana, alcohol, fry1, powder cocaine, 
heroin, speedball (a mixture of heroin and cocaine) and codeine syrup?” Drug use 
indicators were denoted as: “never use” (0) or “have ever used” (1). Also, age was 
                                                 
1 Fry: embalming fluid and phencyclidine (PCP)-laced cigarettes or marijuana sticks 
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considered as an indicator variable because age has been associated with drug use 
types. (Bluthenthal, Wenger, Chu, Bourgois, & Kral, 2017; Golub, Johnson, & Dunlap, 
2005) Based on a median age of 42, participants were categorized as “< 42 years old” 
(0) or “≥ 42 years old”.  
Statistical analysis 
We applied LCA to identify drug use latent classes among our MSM sample. An LCA 
model uses a maximum likelihood approach to identify subgroups or classes of 
individuals with similar patterns of responses to a set of indicator variables (A. L. 
McCutcheon, 1987; Whitesell et al., 2006).  Based on indicator variables, LCA assigns 
each individual a probability of membership in the postulated multilevel latent variable 
(Allan L McCutcheon, 2002). LCA assumes homogeneity within a class, heterogeneity 
among classes, and that the difference in response to items within a class is only due to 
random error (A. L. McCutcheon, 1987; Whitesell et al., 2006).  
We started with a 1-class model and increased the number of classes through 6-class 
models. To obtain the global not local maxima for each model, we used 5,000 random 
starts. We used BIC (the Bayesian Information Criteria), BLRT (the parametric bootstrap 
likelihood ratio test), and LMR (the Lo-Mendell-Rubin adjusted likelihood ratio test) to 
select the model. In addition, we used entropy, a standardized summary measure of the 
classification accuracy, to evaluate the precision of individual assignment based on their 
model-based posterior probabilities. Entropy ranges from 0 to 1, and the higher entropy 
value reflects the better classification (Ramaswamy, DeSarbo, Reibstein, & Robinson, 
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1993). We based our final latent class solution on not only statistical significance, but 
also substantive criteria, e.g., the epidemiological explanation of drug use. 
After latent class identification, we conducted logistic regression models to examine the 
association between class membership and HCV status, sociodemographic 
characteristics, sexual behaviors, and sexual transmitted disease history. We used the 
AUXILIARY (r) option (Muthñn & Muthñn, 2012) for the multinomial logistic regression 
estimation. This technique incorporates the posterior-probabilities of membership into 
the estimation procedure, and helps examine the fidelity and utility of the specific latent 
class profiles (Petras & Masyn, 2010). We conducted bivariate associations of latent 
class of drug use with each independent variable. Independent variables with a P-value 
less than 0.25 were entered into the joint model, which allowed us to evaluate the 
adjusted relationships between membership in a particular drug use class and HCV 
infection. We used Mplus 6.1 (Muthén & Muthén, CA) to conduct the LCA model 
building and multi-nominal and multivariable logistic regression and SAS 9.4 (Cary, NC) 
to manage the data. 
RESULTS 
In the DASH parental project study, the prevalence of HCV was 36.1% among 2,800 
who used drugs and were contacted for HIV/HBV/HCV screening. The predominant risk 
characteristic associated with HCV infection was injection drug use (70% prevalence). 
(Hwang & Grimes, 2012). Among 273 MSM who reported drug use not including 
injection drug use, the HCV prevalence was 14.7%. Only age was significantly 
associated with HCV infection. Compared to participants who were less than 42 years 
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old, those age 42 or older had 2.1 times the odds of having HCV infection (95%CI: 1.4-
3.0).  
 
Among 273 MSM who reported drug use not including injection drug use, we analyzed 
118 MSM who participated in the baseline interview, among whom 21 (17.8%) were 
infected with HCV. Table 1 presents the sociodemographic characteristics and 
behavioral variables for the analytical sample. For sociodemographic characteristics, 
the age of the participants ranged from 19 to 61 years old with the mean of 39.6 years 
old (IQR: 35-46), 83% were African American, 83% reported sexual orientation as 
bisexual or homosexual, 76% had less than a high school education or completed high 
school only, 65% were single, 50% worked less than 14 days in the past month, 50% 
had an income less than 400 dollars in the past month, 46% had been homeless at 
least once, 76% had been arrested and spent more than 24 hours in jail, and 35% never 
received drug treatment. For sexual risk behaviors, 41% of the participants had 0 or 1 
male sexual partners in the past month, about two thirds of them used condoms less 
than half of the time while having sex, about two thirds of the participants had traded 
sex for money or drugs in the past month, more than half had traded money for drugs or 
sex in the past month. Regarding disease history, 45% had been diagnosed with STIs. 
Regarding drug use behavior, the majority of participants had used multiple drugs 
(defined as had ever used more than 2 drugs), and the most prevalent drug types were 
crack cocaine (98%), marijuana (89%), and alcohol (86%). The prevalence of other 
types of drug use were 57% for powder cocaine, 22% for codeine, 21% for fry, 14% for 
methamphetamine, 6.8% for heroin, and 3.4% for speedball. 
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For LCA, Table 2 presents the results of statistics and entropy for 1- through 6- latent 
classes. Although the BIC value was the lowest at the 2-class model solution, LMR 
supported for all 2- through 5- class model (p-value <0.05) and BLRT supported for 2- 
through 4- class model. Entropy showed that all 3- through 6- class models had 
satisfied precision (entropy >0.8). Therefore, both 3- and 4- class models were 
preferable. Based on statistical significance and practical utility, we selected the 4-class 
model as the best fit model.  
Figure 2 shows the estimated probability of the 4-class model. Participants in class 1, 
accounted for 6.5% of the sample, had high probability (>95%) of using only crack 
cocaine and the lowest probability of using all other types of drugs, with 75% probability 
of being 42 years old or above. We referred to class 1 as “persons >=42 years old who 
used only cocaine”.  Class 2 members accounted for 70.3% of the sample, had high 
probability (>90%) of using crack cocaine, marijuana, and had moderate probability 
(50%) of using powder cocaine, with a half of the probability of being 42 years old or 
above. We referred to class 2 as “persons about 42 years old who used >2 drugs”. 
Class 3 members accounted for 20.1% of the participants, had high probability (>90%) 
of using crack cocaine, marijuana, powder cocaine, and especially compared with all 
other classes, class 3 members had the highest probability of using fry and codeine; the 
probability of being 42 years old or above was only 35%. We referred to class 3 as 
“persons <42 years old who used >5 drugs”. Individuals in class 4 accounted for 3.2% 
of the sample, had high probability of using all types of drugs except for fry and codeine, 
specifically, the probability of using methamphetamine, heroin, and speedball were the 
highest among individuals in class 4 compared to all other classes, and the probability 
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of being 42 years old or above were very high (>99%). We referred to class 4 as 
“persons >=42 years old who used>6 drugs”.  
Table 3 presents the results of our bivariate multinomial logistic regression. We found 
that only HCV status was significantly associated with drug use latent classes. 
Compared with the members in other classes, class 4 members had the highest 
possibility of having HCV infection. The odds of having HCV infection among class 4 
members was 14 times (OR=14.2, 95%CI: 1.3-157.4) the odds of having HCV infection 
among those who in class 2, and was 20 times (crude OR=20.5, 95%CI: 1.4-291.7) the 
odds of having HCV infection among those who in class 3. The probability of having 
HCV also showed higher in class 4 members than class 1 members, but the results was 
not statistically significant (crude OR=7.8, 95%CI: 0.5-134.7). For the associations 
between drug use classes with other variables, such as sociodemographic 
characteristics, sexual behaviors, self-reported STI history, blood transfusion history, 
and occupational blood exposure history, all the results were not statistically significant. 
Table 4 presents the results of our multivariable regression model. We entered drug 
treatment history, self-reported STI history and trading money or drugs for sex in the 
past month in the model (these variables had p-values<0.25 in the bivariate analysis) to 
adjust for the association between drug use class and HCV infection. The results 
showed that HCV infection status was significantly associated with drug use classes. 
Compared with class 2 members, class 4 members had close to 17 times the odds of 
having HCV infection (adjusted OR = 16.9, 95%CI: 1.4-205.4), and compared with class 
3 members, class 4 members had close to 22 times the odds of having HCV infection 
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(adjusted OR=21.8, 95%CI: 1.5-322.8), controlling for drug treatment history, self-
reported STI history and trading money or drugs for sex in the past month. 
DISCUSSION 
In this study, we applied LCA to identify latent classes among MSM who reported drug 
use but did not report injection use of drugs. We found four distinct latent classes, which 
were class 1, persons >=42 years old who used only crack cocaine; class 2, persons 
about 42 years old who used >2 drugs; class 3, persons <42 years old who used >5 
drugs; and class 4, persons >=42 years old who used >6 drugs. We also found 
associations between certain latent classes of drug use and HCV infection. After 
adjusting for drug treatment history, self-reported STI history, and behavior of trading 
money or drugs for sex in the past month, we found that persons >=42 years old who 
used >6 drugs had close to 17 times the odds of having HCV infection, compared with 
persons about 42 years old who used >2 drugs, and close to 22 times the odds of 
having HCV infection, compared with persons <42 years old who used >5 drugs. 
Among participants who were 42 years old or above, the membership of drug use latent 
class was polarized. Members in one class (class 1) only used crack cocaine, whereas 
members in the other class (class 4) used multiple drugs, including crack cocaine, 
marijuana, powder cocaine, methamphetamine, heroin, and speedball. The members in 
class 4 had a higher HCV infection probability than those who were in class 1, but the 
difference was not statistically significant. However, we need to interpret this non-
significant result cautiously, because the sample sizes in the two classes accounted for 
only 3.2% and 6.5% of the sample, respectively, which limited the statistical power of 
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the study to detect the differences in HCV infection probabilities between these two 
classes. 
The mean age for the class 3 members was slightly lower than that for the class 2 
members. The class 3 members had higher probability of using fry and codeine than the 
class 2 members, which is consistent with previous reports in the 1990s of fry (Modesto-
Lowe & Petry, 2001; Peters Jr et al., 2005) and codeine abuse (Elwood, 2001; Peters Jr 
et al., 2007), especially among teenagers. The results of the present study showed that 
compared with participants who used crack cocaine and marijuana, those who 
additionally used fry and codeine did not have a higher probability of HCV infection. One 
reason may be that people normally take fry by smoking it and codeine in the form of 
syrup, pill, or drinks (mixed with soda). All these administrative routes have a lower 
likelihood of blood exposure that may lead to HCV infection and transmission. However, 
studies have reported an increase of sexual risk behavior among people who use of fry 
or codeine (Peters Jr et al., 2007), but these studies were not restricted to MSM. The 
present study, which was restricted to MSM, found that the use of fry or codeine were 
not associated with sexual risk behaviors. 
By comparing latent classes of drug use with different ages, we found an interaction 
effect between age and drug use types on the probability of HCV infection. This finding 
indicates that age and drug use types were both associated with HCV infection, and that 
differences in age were linked to different preference of drug use types. The participants 
who had multiple use of heroin, speedball, and methamphetamine, in addition to the 
commonly used crack cocaine and marijuana, were all 42 years old or above, which 
formed a latent class that had a much higher HCV infection probability than that of other 
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latent classes. On the one hand, some previous studies revealed that individuals born 
between 1945-1965 had a higher HCV infection rate than that of other individuals; 
conversely, other previous studies implied that the use of heroin, speedball, and 
methamphetamine may relate to HCV infection from several perspectives. First, 
repeated intranasal use of heroin, cocaine (speedball is heroin mixed with cocaine), and 
methamphetamine may cause mucosal trauma and hyperemia (Bakhshaee, Khadivi, 
Sadr, & Esmatinia, 2013; Blaise, Vanhooteghem, & De La Brassinne, 2007; Peyrière et 
al., 2013; Trimarchi et al., 2006), and HCV has been detected in nasal secretions 
(Aaron et al., 2008) in people with HCV infection. Second, drug use paraphernalia are 
often shared among people who use drugs, and HCV RNA may remain in the 
paraphernalia for up to 16 hours (Kamili, Krawczynski, McCaustland, Li, & Alter, 2007). 
Third, people who use heroin, speedball, and methamphetamine may be exposed to 
social networks with a higher HCV infection rate than those who use other drugs, 
because a proportion of people who use heroin, speedball, and methamphetamine 
inject these drugs, and 40%-90% of people who inject drugs are infected with HCV 
(Gerberding, 1994; Hagan, Pouget, Des Jarlais, & Lelutiu-Weinberger, 2008). However, 
some studies have not found that sharing straws or dollar bills when snorting drugs 
among people who do not report injection drug use is associated with HCV infection 
(Gyarmathy, Neaigus, Miller, Friedman, & Jarlais, 2002; Howe et al., 2005). More 
research is needed to determine whether sharing equipment for non-injection drug use 
is a transmission route of HCV or not. 
We cannot directly compare the present LCA findings with those of previous LCA 
findings because of different recruitment strategies, indicator variables, and the disease 
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of interest. However, our findings are consistent with other findings demonstrating high 
rates of infectious diseases, such as HIV, among people who used multiple drugs 
(Buchacz et al., 2000; Chitwood, Comerford, & Sanchez, 2003; Drumright & Colfax, 
2009; Vallejo et al., 2008). LCA studies in MSM have demonstrated that multiple drug 
use is also associated with increased transmission of STIs by disinhibiting sexual risk 
behavior (Lim et al., 2015; Yu et al., 2015); the present study did not find as association 
between multiple drug use and STIs. One reason of this lack of association may be that 
individuals with HIV and/or HBV infection were excluded from the baseline data of 
DASH project, which may in turn, lead to the exclusion of individuals also coinfected 
with STIs; thus, underestimating the effect of multiple drug use on STIs or risky sexual 
behavior in our sample of MSM.  
This study had some limitations. First, we had small sample size for some drug use 
subgroups identified by LCA. During analysis, we tested multiple combinations of 
different variable classifications, and only the reported subgroup solution showed a 
significant association with HCV infection.  However, although was statistically 
significant, it also had very large confidence intervals for the significant results; thus, we 
must interpret the results with caution. Second, for some variables assessing sexual risk 
behaviors, this study might not have sufficient power to identify their effects on HCV 
transmission. Third, the route of drug use, and information regarding sharing equipment 
for drug use were not collected in this study, which may provide crucial information on 
HCV transmission route in this population (Tortu, McMahon, Pouget, & Hamid, 2004). 
Fourth, although drug use was verified by lab testing, drug use types and sexual risk 
behaviors were self-reported, which may have led to underreporting. Fifth, the cross-
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sectional study design may not confirm the temporality of the risk behaviors and HCV 
infection. Lastly, some information potentially related to sexual transmission of HCV was 
not collected in this study, e.g., drugs related to sex (MDMA, LSD, etc.), and sexual 
behaviors such as anal sex and group sex. Future studies are warranted with larger 
sample size, collecting additional information on administrative routes of drug use, sex-
related drugs, and detailed sexual risk behaviors of MSM. Further, a longitudinal study 
design may help clarify the temporality of risk behaviors and HCV infection and explore 
the transition between drug use subgroups, which may provide insightful understanding 
of association between drug use behavior and the risk of HCV infection. 
Despite these limitations, this study has several strengths. To the best of our 
knowledge, this is the first study to evaluate the association of latent class of non-
injection drug use and HCV infection among HIV-negative MSM by using latent class 
analysis. Because LCA reduced the dimension of drug use types, this study discovered 
and evaluated the interaction effect between age and multiple drug use types on HCV 
infection, which very few studies have reported. In addition, this study excluded 
individuals with HIV and/or HBV infection; thus, although it led to a smaller sample size 
for this study, we demonstrated that in the absence of HIV and HBV, there was still a 
strong association between the interaction of age and multiple drug use types on HCV 
infection. 
In conclusion, we found four distinct latent classes of drug use among MSM: (1) 
persons >=42 years old who used only crack cocaine, (2) persons about 42 years old 
who used >2 drugs, (3) persons <42 years old who used >5 drugs, and (4) persons 
>=42 years old who used >6 drugs. Persons >=42 years old who used >6 drugs was 
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associated with increased probability of HCV infection. Health education and promotion 
programs geared towards this subgroup of MSM are needed to increase the awareness 
of HCV infection, and subsequently increase testing and treatment rates for HCV. 
Furthermore, drug treatment programs or rehabilitation programs are also needed to 
reduce the physical damage of multiple drug use and the probability of acquiring or 
transmitting HCV, especially among heavy multiple drug use MSM. 
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Table 1 Characteristics of 118 HIV-negative MSM who reported drug use but did not 
report injection drug use in Houston, TX 
Characteristics n % 
Latent class indicators a    
    Crack cocaine 116 98.3 
    Methamphetamine 17 14.4 
    Marijuana 105 89.0 
    Alcohol 101 85.6 
    Fry 25 21.2 
    Powder cocaine 67 56.8 
    Heroin 8 6.8 
    Speedball 4 3.4 
    Codeine 26 22.0 
    42 years old or above 59 50 
Sociodemographic characteristics   
    African American 98 83.1 
    Self-reported homosexual or bisexual 98 83.1 
    Education level (less than or equal to high school) 90 76.3 
Marital status (single) 77 65.3 
    Worked less than 14 days in past 30 days 58 49.2 
    Income less than 400 dollars in the past month  70 59.3 
    Homeless  54 45.8 
    Had been in jail for more than 24 hours 90 76.3 
    Never received drug treatment 41 34.7 
Sexual behaviors   
    Had 0 or 1 male sexual partner in the past month  48 40.7 
    Condom use frequency (<=50%)  71 60.7 
    Traded sex for money or drugs in the past month 74 62.7 
    Traded money or drugs for sex in the past month 68 57.6 
Diseases status    
    Had sexual transmitted disease history 53 44.9 
Blood exposure    
    Had blood transfusion history 4 3.4 
    Had occupational blood exposure history 7 5.9 
a These variables refer to the response to the question: “have you ever used this drug” 
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Table 2 Statistics and entropy of latent class analyses 
classes LLa Free 
parameters 
BICb LMRc BLRTd Entropy 
1 -462.630 10 972.966 NA NA NA 
2 -430.427 21 961.039 0.0001 0.0000 0.731 
3 -418.644 32 989.950 0.0177 0.0100 0.957 
4 -406.801 43 1018.742 0.0424 0.0400 0.963 
5 -400.104 54 1057.826 0.0115 0.4000 0.957 
6 -394.546 65 1099.186 0.1469 0.6200 0.978 
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Table 3 Bivariate associations between latent class membership and characteristics of 118 HIV-negative MSM who 
reported drug use but not injection drug use in Houston, TX  
Characteristics Class 4 vs 1 
cOR (95%CI)* 
Class 4 vs 2 
cOR (95%CI) 
Class 4 vs 3 
cOR (95%CI) 
Class 1 vs 2 
cOR (95%CI) 
Class 1 vs 3 
cOR (95%CI) 
Class 3 vs 2 
cOR (95%CI) 
Sociodemographic       
African American vs  
Caucasian or Hispanic 
14621447  
(0.0-I) 
1.5  
(0.1-16.3) 
2.7  
(0.2-40.2) 
0.0  
(0.0-I) 
0.0  
(0.0-I) 
0.5 
 (0.1-2.4) 
Homosexual or bisexual vs  
heterosexual 
0.0  
(0.0-I) 
0.0  
(0.0-I) 
0.0  
(0.0-I) 
2.2  
(0.4-12.7) 
0.9  
(0.1-6.3) 
2.3  
(0.7-7.2) 
Less than or equal to high school vs  
higher than high school 
0.0  
(0.0-I) 
0.4  
(0.0-3.7) 
0.3 
(0.0-3.1) 
9175065  
(0.0-I) 
6382051  
(0.0-I) 
1.4  
(0.4-4.7) 
Single vs  
married, live with partner, separated, divorced, 
widowed 
20.5  
(0.0-
2.12E189) 
5.5  
(0.5-58.6) 
4.0 
(0.3-47.6) 
0.3  
(0.0-2.75E187) 
0.2  
(0.0-2.03E187) 
1.4  
(0.5-3.6) 
Days of working in the past month: 
<14 days vs >=14 days  
1980777  
(0.0-I) 
17175594  
(0.0-I) 
27371147  
(0.0-I) 
8.7  
(0.0-1.99E192) 
13.8  
(0.0-3.17E192) 
0.6 
(0.2-1.7) 
Income in the past month:  
<400 dollars vs >= 400 dollars 
11.6  
(0.0-I) 
64.8  
(0.0-I) 
85.0  
(0.0-I) 
5.6  
(0.0-2.27E198) 
7.3  
(0.0-2.98E198) 
0.8  
(0.3-2.0) 
Ever homeless vs never homeless  0.2  
(0.0-3.4) 
0.4  
(0.0-4.4) 
0.5  
(0.0-6.2) 
2.0  
(0.4-9.7) 
2.5  
(0.4-14.3) 
0.8  
(0.3-2.1) 
Had been in jail for more than 24 hours: 
Yes vs No 
7195742  
(0.0-I) 
4239687  
(0.0-I) 
2340792  
(0.0-I) 
0.6  
(0.1-3.0) 
0.3  
(0.0-2.2) 
1.8 
 (0.5-6.3) 
Never received drug treatment vs  
received drug treatment 
0.7  
(0.0-12.0) 
0.6  
(0.1-6.2) 
1.2  
(0.1-15.6) 
0.8  
(0.1-4.6) 
1.8  
(0.3-12.1) 
0.5  
(0.2-1.5) 
Sexual behavior       
No. of male sexual partners in the past month:   
0 or 1 vs >1 
0.0 
(0.0-I) 
0.0  
(0.0-I) 
0.0  
(0.0-I) 
1.2  
(0.2-6.1) 
1.0 
 (0.2-5.6) 
1.2 
(0.5-3.3) 
Condom use frequency while having sex:  
<=50% vs >50% 
0.7  
(0.1-10.0) 
0.8  
(0.1-7.2) 
0.6 
(0.1-5.8) 
1.1  
(0.2-5.2) 
0.8  
(0.1-4.5) 
1.4  
(0.5-3.9) 
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Characteristics Class 4 vs 1 
cOR (95%CI)* 
Class 4 vs 2 
cOR (95%CI) 
Class 4 vs 3 
cOR (95%CI) 
Class 1 vs 2 
cOR (95%CI) 
Class 1 vs 3 
cOR (95%CI) 
Class 3 vs 2 
cOR (95%CI) 
Traded sex for money or drugs in the past 
month 
Yes vs No 
2.8  
(0.2-42.8) 
1.7  
(0.2-17.8) 
1.3  
(0.1-16.0) 
0.6  
(0.1-2.9) 
0.5  
(0.1-2.7) 
1.2  
(0.5-3.4) 
Traded money or drugs for sex in the past 
month 
Yes vs No 
2.5  
(0.2-39.1) 
2.3  
(0.2-24.6) 
1.2  
(0.1-14.9) 
0.9  
(0.2-4.5) 
0.5  
(0.1-2.9) 
1.9  
(0.7-5.2) 
Blood exposure history       
Had blood transfusion 
Yes vs No 
12310954  
(0.0-I) 
14.7  
(1.0-220.7) 
9.7  
(0.0-
3.07E257) 
0.0  
(0.0-I) 
0.0 
(0.0-I) 
1.5  
(0.0-
4.83E256) 
Had occupational blood exposure 
Yes vs No 
2.0  
(0.0-I) 
0.0  
(0.0-I) 
6.3  
(0.0-I) 
0.0  
(0.0-I) 
3.1  
(0.0-I) 
0.0  
(0.0-I) 
Disease history       
Had STI*** 
Yes vs No 
1.6  
(0.1-25.4) 
4.4  
(0.4-46.4) 
2.1  
(0.2-25.0) 
2.8  
(0.5-14.0) 
1.4  
(0.2-7.9) 
2.1  
(0.8-5.4) 
Had HCV infection 
Yes vs No 
  
7.8  
(0.5-134.7) 
14.2 ** 
(1.3-157.4) 
20.5 ** 
(1.4-291.7) 
1.8  
(0.3-10.6) 
2.6  
(0.3-21.8) 
0.7  
(0.2-3.0) 
* cOR: crude odds ratio 
** P<0.05 
*** STI: Sexually transmitted infections 
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Table 4 Multivariable association between latent class membership with characteristics in 118 HIV-negative MSM who 
reported drug use but not injection drug use in Houston, TX 
Characteristics Class 4 vs 1 
aOR* (95%CI) 
Class 4 vs 2 
aOR (95%CI) 
Class 4 vs 3 
aOR (95%CI) 
Class 1 vs 2 
aOR (95%CI) 
Class 1 vs 3 
aOR (95%CI) 
Class 3 vs 2 
aOR (95%CI) 
Never received drug treatment vs  
received drug treatment 
0.8  
(0.0-17.0) 
0.7  
(0.1-9.8) 
1.2  
(0.1-19.7) 
0.9  
(0.1-5.1) 
1.5  
(0.2-11.0) 
0.6  
(0.2-1.9) 
Had STIs*** vs Never had STI 
1.9  
(0.1-33.5) 
5.3  
(0.4-65.3) 
2.7  
(0.2-36.6) 
2.8  
(0.5-14.6) 
1.4  
(0.2-8.6) 
2.0  
(0.7-5.3) 
Traded money or drugs for sex in the 
past month vs never traded money or 
drugs for sex in the past month 
2.5  
(0.1-48.4) 
2.4  
(0.2-33.2) 
1.4  
(0.1-21.6) 
1.0  
(0.2-4.8) 
0.6  
(0.1-3.4) 
1.7  
(0.6-5.0) 
Had HCV infection vs Did not have 
HCV infection 
8.5  
(0.5-154.0) 
16.9 ** 
(1.4-205.4) 
21.8 ** 
(1.5-322.8) 
2.0  
(0.3-12.2) 
2.6  
(0.3-22.2) 
0.8  
(0.2-3.5) 
* aOR: adjusted odds ratio 
** P<0.05 
*** STI: Self-reported sexually transmitted infections 
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 Figure 1. DASH study population flow chart 
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Figure 2 Probability of each indicator variable in each class of 4-latent class model 
Note:  
Class 1 (6.5%): persons >=42 years old who used only cruck cocaine; 
Class 2 (70.3%): persons about 42 years old who used >2 drugs; 
Class 3 (20.1%): persons <42 years old who used >5 drugs; 
Class 4 (3.2%): persons >=42 years old who used >6 drugs. 
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Article III: Risk factors associated with HCV infection in young men who have 
sex with men reporting drug use not including inject drug in Houston, TX 
This article has been formatted for the Journal of BMC Public Health 
 
ABSTRACT 
Background: Hepatitis C (HCV) infection in men who have sex with men (MSM) 
has been increasingly reported in recent years. However, little is known about HCV 
infection in young MSM (YMSM).  
Methods: From 2014 to 2017, we recruited YMSM (aged between 17-29 years) who 
reported drug use, but not injection drug use, in Houston, Texas. We collected 
information on sociodemographic characteristics and sexual risk behaviors of 
participants and their sexual partners. We also tested participants for HIV, syphilis, 
and anti-HCV. Generalized estimating equations were used to assess the 
association between HCV infection and a variety of exposures. 
Results: Among 983 participant-partner dyads, we found that syphilis/HIV 
coinfection was significantly associated with having anti-HCV of the participants. 
Compared with the odds of having anti-HCV among reference group (participants’ 
syphilis mono-infection, HIV mono-infection, and neither syphilis nor HIV infection), 
the odds of having anti-HCV among syphilis/HIV co-infected participants is 4.5times 
higher (aOR=4.5, 95%CI: 1.05-18.76), controlling for age similarity, participants’ HIV 
status, and whether the participant and his sexual partner used drug before sex.  
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Conclusion: Syphilis/HIV co-infection was all associated with increased HCV 
infection. Treatment of syphilis and/or HIV may reduce the disease burden of HCV in 
YMSM who reported drug use not including injection drug use. 
 
INTRODUCTION 
Since 2000, there have been increasing reports of a hepatitis C virus (HCV) 
epidemic and outbreaks among HIV-positive men who have sex with men (MSM) in 
Northern Europe, North America, and Australia [1-4]. One meta-analysis reported 
that the pooled estimated incidence rate of HCV infection among HIV-positive MSM 
was 19 times that among HIV-negative MSM [5]. Another meta-analysis reported 
that the pooled HCV prevalence is 8.1% [6], much higher than that in the rest of the 
general population in the United States (1%) [7]. The epidemic of HCV in MSM has 
been linked to high-risk sex behaviors, such as group sex with unprotected anal 
intercourse (UAI) [4, 8], fisting [4, 9]; rectal trauma with bleeding [10]; and potentially 
underreported non-injection drug use [9, 11, 12]. 
 “Chemsex” is the use of drugs before or during sex to enhance sexual arousal, 
performance and disinhibition. It has been shown to influence sexual risk behaviors 
in this population [13-16]. In recent years, a growing number of studies reported 
chemsex in MSM, and found that the prevalence of chemsex ranged from 3% to 
29% among MSM recruited from public venues, gay venues, gay pride event, sexual 
health clinic, internet, and so on [17]. Chemsex is associated with sexual risk 
behaviors, including UAI  [17-19], being fisted [19, 20], and group sex [20]. Chemsex 
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is also associated with new HIV infection [21], acute sexually transmitted infections 
(STI) [18, 21, 22], and HCV infection [18, 21, 23]. 
Besides “chemsex”, MSM also disproportionately shared the disease burden of 
syphilis and HIV. The incidence of syphilis and HIV infection in MSM [24, 25], 
especially in young MSM (YMSM) have been increasing in recent years, which might 
also contribute to the reported epidemic of HCV in MSM. In the United States, 
reported primary and secondary (P&S) syphilis increased 10.5% between 2016 and 
2017 [26]. Males accounted for more than 90% of new cases of syphilis infection 
from 2009 to 2013, among whom, MSM who were 25-29 years old had the greatest 
increase among all age groups (48.4%, 18.2 to 27.0 per 100,000 population) [27]. 
Moreover, for the incidence of HIV infection in the United States, MSM accounted for 
two thirds of new infections in 2010 [28]. In reported cases from 2008 to 2011, MSM 
who were aged 25-34 years accounted for the highest proportion, while MSM aged 
13-24 years had the fastest growing rate of infection [29]. 
Although research on the sexual transmission of HCV in MSM has increased, most 
studies have focused on HIV-positive MSM and/or MSM who inject drugs. In 
addition, little is known of HCV risk factors specific to YMSM, which may be a 
particularly vulnerable subgroup of MSM. Furthermore, most of the information used 
in such studies is at an individual level, which may not adequately reflect the 
dynamics of disease transmission. To fill this knowledge gap, we analyzed 
participant-partner dyadic data of YMSM who reported drug use not including 
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injection drug use, a subset from the parental study of the Young Men Affiliation 
Project (YMAP). According to Neaigus, the dyadic link is the primary unit in network 
development; thus, dyadic data analysis may yield useful results and is feasible 
among hidden populations, such as MSM [30]. The objective of the study is to 
assess the associations between the characteristics of participants, sexual partners 
and characteristics of partnership in a subset of egocentric sexual networks of 
YMSM and the likelihood that participants are infected with HCV.  
METHODS 
Study setting 
Data were obtained from the Young Men’s Affiliation Project (YMAP), a longitudinal 
network study collected from 2014 to 2017 to investigate social networks and 
attendance history at social venues and health-promoting venues among YMSM, 
and to determine how these networks affect HIV and sexually transmitted disease 
risk and prevention in Houston and Chicago [31-33]. For Houston site, participants 
were included in this study if they identified as male sex assigned at birth and 
current male identification, were aged between 17-29 years, reported oral or anal 
sex with another male in the past 12 months, were residing in and planning to 
remain in Houston for the following year, and were English-speaking. The study was 
approved by the institutional review boards at each institution (HSC-SPH-12-0830). 
Participant recruitment and data collection 
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The sampling method in the YMAP study was respondent driven sampling (RDS) 
[34]. This method has been applied to recruit hard-to-reach populations, such as 
MSM and people who use drugs. The “seeds” were defined as participants enrolled 
via representatives at health service providing facilities or at social venues. “Sprouts” 
were defined as participants who were referred by “seeds”. Four vouchers were 
given to each participant to recruit other YMSM (sprouts) to produce chained 
samples.  
Interviews were conducted using a computer-based personal-interview combined 
with a computer-assisted self-interview delivered via Qualtrics (Qualtrics LLC, Provo, 
Utah). In the computer-assisted personal interviews, the trained data collector read 
questions from the computer and entered data. We collected information on 
sociodemographic characteristics, drug use, social and sexual networks, behavior 
with peers, and participants’ affiliation with community organizations and 
businesses. For sexual networks, each participant was asked to nominate up to 5 
sexual partners in the past 6 months. We collected participants’ perception of each 
sexual partner’s sociodemographic characteristics, behavioral measures, HIV status, 
as well as partnership-level information between the participant and each of his 
partner’s sexual behavioral measures. 
Laboratory testing 
After the interview, each participant provided biological blood specimen for HIV, 
HCV, and syphilis testing. HIV tests included fourth generation rapid test, using 
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Alere Determine HIV-1/2 Ab/Ag combo (Abbott Laboratories, Chicago, IL), viral load 
quantitative test, using Cobas AmpliPrep/Cobas TaqMan HIV-1 test kit, version 2,0 
(Roche Molecular Diagnostics, Pleasanton, California), and confirmatory test, using 
Geenius HIV -1/2 Confirmatory test (Bio-rad, Marnes-la-Coquette, France). Syphilis 
tests included a rapid plasma regain (RPR) test, using the Macro-Vue RPR Card test 
Kit (BD Diagnositics, Franklin Lakes, New Jersey), and fluorescent treponemal 
antibody FTA test, using Immunofluorence Assay FTA-Absorption Test System 
(Zeus Scientific, Branchburg, New Jersey). HCV test was HCV antibody rapid test 
(Boson Biotech, Xiamen, China).  
HIV infection was defined as rapid test positive and viral load detectable, or viral 
load undetectable but confirmation test positive. Syphilis infection was defined as 
FTA test positive and RPR titer equal to or greater than 1:8. [35] HCV infection was 
defined as repeated positive results from rapid antibody test.  
Study sample and measures 
The study sample was a subset of YMAP baseline data restricted to participants who 
reported never having injected drugs. The outcome variable was participant’s HCV 
status and the independent variables included three sets: (a) participant’s 
characteristics, (b) perceived sexual partner’s characteristics, and (c) dyadic 
measures between a participant and each of his sexual partner’s sexual behaviors.  
For participants’ measures, we used sociodemographic information (age, education 
level, race/ethnicity, employment status, living arrangement, insurance status, and 
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have ever been in jail for more than 24 hours), sexual risk behavioral information 
(group sex and number of sexual partners in the past 6 months), and disease status 
(HIV and syphilis infection status). For participants’ perception of sexual partner’s 
characteristics, all data were treated as clustered data on the participant, including 
sociodemographic information (age, gender, education level, and race/ethnicity), and 
sexual risk behavioral information (unprotected sex, HIV infection status and drug 
use). For participants’ perception of sexual network dyadic measures, all data were 
also treated as clustered data on the participant, including sexual behavioral 
measures (whether shared drugs, times that had sex, whether had anal sex, 
whether the participant ever had receptive anal sex, consistent condom use, 
whether used drugs before sex, whether engaged in group sex together) and 
homophily/similarity measures with respect to age, race/ethnicity, and HIV 
serostatus. We defined age homophily as the value of age difference between a 
participant and his nominated sexual partner; race/ethnicity homophily as 1=black 
with black, 2=black with non-black or non-black with black (dissortativity), and 
3=non-black with non-black; and HIV serostatus homophily as 1= participant HIV 
seropositivity and participant’s perception about sexual partner’s positivity, 
2=participant HIV seropositive and participant’s perception about sex partner 
negative, 3=participant HIV seropositivity and participant’s perception about sex 
partner’s unknown, 4=participant HIV seronegative and participant’s perception 
about sex partner positive, 5=participant HIV seronegative and participant’s 
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perception about sex partner negative, and 6=participant HIV seronegative and 
participant’s perception about sex partner unknown. 
Statistical analysis 
The unit of analysis was the sexual dyad, which was a pair composed of a 
participant and each of his nominated sexual partners. We conducted Chi-square 
tests and Fisher exact tests to assess the differences of HCV status between the 
categories of each independent variable. We also conducted bivariate and 
multivariable generalized estimating equation (GEE), which can deal with clustered 
observation of participants[36] to statistically test the association between HCV 
status and independent variables. We used autoregressive correlation structure and 
robust estimates to address potential misspecification of variance structure. Bivariate 
analyses were performed between HCV status and each independent variable, 
showing crude odds ratio and 95% confidence intervals. For variables with p-values 
less than 0.25 in bivariate analyses, we included all of them, except syphilis mono-
infection, into multivariable GEE model. We excluded syphilis mono-infection 
because this variable and syphilis/HIV co-infection had collinearity. We finally 
assessed the interaction effect between the selected independent variables in a 
multivariable model. The statistical significance level was set at 5%. We used SAS 
9.4 (Cary, NC) to manage the data and conduct the GEE analysis. 
RESULTS 
Participants’ characteristics 
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Among 378 participants of YMAP study, we excluded 5 participants who reported 
never used any drugs, 4 participants who reported injection drug use behavior, 3 
participants who did not report injection drug use information. We finally identified a 
total of 366 MSM who reported drug use not including injection drug use, among 
whom 12 (3.3%) had anti-HCV. Table 1 shows the characteristics of participants 
stratified by HCV status. In terms of sociodemographic characteristics, age ranged 
from 17 years to 29 years with a median of 25 years. Of the participants, 63% had 
more than a high school education level; 63% were black; 19% were Hispanic; 49% 
were employed;18% were homeless in the past month; 59% had insurance; and 
40% had ever been in jail for more than 24 hours. In terms of sexual risk behaviors, 
28% engaged in group sex; 44% had 2 to 5 sexual partners in the past 6 months. In 
terms of disease status, 38% were HIV positive and 16% were syphilis positive; 12% 
were co-infected with HIV and syphilis. Chi-square or Fisher exact tests show that 
HCV status differed significantly between HIV-positive and HIV-negative 
participants, as well as between positive syphilis and negative syphilis participants. 
Participants’ sexual partners’ perceived characteristics and dyad measures 
A total of 983 sexual partners were nominated by participants. Table 2 shows the 
participants’ perceived characteristics of sexual partners and dyadic measures 
between a participant and his sexual partners stratified by participants’ HCV status. 
For socio-demographic characteristics of sexual partners, age ranged from 19 years 
to 65 years, with a median of 26 years; 92% were male; 50% had more than a high 
school education level; 51% were black; 22% were Hispanic. For behavioral 
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measures and disease status of sexual partners, 44% had unprotected sex; 11% 
were participant perceived HIV positive and 27% had unknown HIV status by 
participants; 39% used drugs. For dyadic measures between participants and their 
sexual partners, 29% shared drugs with participants; 42% had sex 2 to 9 times with 
participants; 88% had anal sex with participants; 52% let participants ever had 
receptive anal sex; 36% had consistent condom use when having sex with 
participants; 30% used drugs before sex; 8% had group sex together with 
participants. For the perceived characteristics of homophily, 70% of the dyads had 
participants’ age younger than sexual partners’ age; 47% of the dyads were black for 
both participants and sexual partners; 8% of the dyads were both HIV-positive and 
49% were both HIV-negative. The results of Chi-square or Fisher exact tests 
showed that HCV status differed significantly in the categories of age homophily and 
HIV status homophily: a participant who was older than his sexual partner had 
higher probability of having anti-HCV than the participant who was younger than his 
sexual partner; a participant who was HIV positive regardless of his sexual partner’s 
HIV status perceived by the participant, had higher probability of having anti-HCV 
than an HIV-negative participant regardless of his sexual partner’s HIV status 
perceived by the participant.  Additionally, whether the participants and sexual 
partners shared drugs (p=0.071) and used drugs before sex (p=0.077) had small p-
value in Chi-square tests. 
Bivariate and multivariable analyses 
 87 
 
For the results of the bivariate GEE model, Table 3 shows the crude odds ratio, 
95%CI, and p-value of Wald tests of each independent variable. As shown, HIV 
status and syphilis status were significantly associated with HCV status (HIV 
cOR=5.31, 95%CI: 1.5-19.3; syphilis cOR=6.6, 95%CI: 1.8-23.8). Age homophily (p-
value=0.12) and whether the participant and his sexual partner used drugs before 
sex (p-value=0.19) both had p-values less than 0.25, so they were included in the 
multivariable model.  
For the multivariable GEE model, we included age homophily, HIV status, syphilis 
status, and whether the participant and his sexual partner used drugs before sex in 
the model. As in the bivariate GEE model, there was an interaction effect between 
HIV status and syphilis status, so we used the interaction variable of HIV and 
syphilis status in the final model. Table 4 shows the adjusted odds ratio and 95%CI 
in multivariable GEE model. As shown, syphilis/HIV coinfection was significantly 
associated with having anti-HCV of the participants. Compared with the odds of 
having anti-HCV among reference group (participants’ syphilis mono-infection, HIV 
mono-infection, and neither syphilis nor HIV infection), the odds of having anti-HCV 
among syphilis/HIV co-infected participants is 4.5 times higher (aOR=4.5, 95%CI: 
1.05-18.76), controlling for age similarity, participants’ HIV status, and whether the 
participant and his sexual partner used drug before sex.  
DISCUSSION 
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In this study, we examined the sociodemographic characteristics and sexual risk 
behaviors of YMSM and their sexual partners to determine risk factors of having 
anti-HCV in this potentially vulnerable subpopulation. We found HIV/syphilis co-
infection, was significantly associated with participants’ anti-HCV, while controlling 
for age homophily between the participant and his sexual partner, participants’ HIV 
status, and whether the participant and his sexual partner used drugs before sex. 
Syphilis infection was found to be associated with HCV infection. This finding is 
consistent with the findings of two studies among women in Chicago and India, 
which reported syphilis infection independently associated with HCV infection [37, 
38]. Similar studies among MSM were mostly restricted to HIV-positive MSM, one of 
which indicated that syphilis infection increased the risk of HCV infection about 5 
times in HIV-positive MSM [39]. In addition, HIV mono-infection has also been found 
to be associated with HCV infection. A systematic review showed the risk of HCV 
infection was 19 times higher among HIV-positive MSM than that among HIV 
negative MSM[5]. The results of the present study were consistent with prior studies, 
showing that syphilis mono-infection and HIV mono-infection were associated the 
increased probability of HCV infection. 
Our study indicates that the syphilis/HIV coinfection group had the highest risk of 
having anti-HCV compared to the risk of having anti-HCV in mono-infection groups, 
and syphilis/HIV coinfection had more than additive interaction effect on HCV 
infection. This finding suggests that there is a link between HIV infection and syphilis 
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infection, which is consistent with prior studies. In the United States, about half of 
syphilis-infected MSM are living with HIV; those who are mono-infected with syphilis 
have a 2- to 5- fold increase of HIV infection than those who are uninfected with 
syphilis[26]. The biological explanations of the overlapped epidemic are syphilis 
infection may cause sores, ulcers or breaks in the skin or mucous membranes that 
provide protection against infection[40]. HIV infection causes suppression of immune 
system. All the aforementioned mechanisms can also be used to explain the effect 
of syphilis/HIV infection on HCV infection transmitted by blood exposure or fluid 
contact.  
All sociodemographic and risk sexual behaviors at both the individual and dyadic 
level were not statistically significant in this study. However, it is worth noting that 
using drugs before sex between the participant and his sexual partner (also referred 
to as “chemsex”) had a smaller p-value (p=0.19) than other sociodemographic and 
risk sexual behavior measures. Although this variable is not statistically significant in 
this study, it is of increasing concern in large MSM communities[41]. Prior studies 
reported that chemsex is associated with HCV infection [18, 21, 23]. However, none 
of the studies were restricted to YMSM. To better evaluate the effect of “chemsex” 
on HCV infection in YMSM, further study may include drug use during sex in addition 
to before sex, and expand the question to any sexual partner instead of restricting to 
nominated sexual partner, which may collect information on “chemsex” to a greater 
extent. 
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This study has several limitations. First, we may not know the HCV status of sexual 
partners, and thus, cannot provide direct evidence of HCV transmission by sexual 
behavior. Second, the anti-HCV rate is relatively low in this YMSM population, which 
may compromise the statistical power.  Third, the cross-sectional design of the study 
cannot provide temporality information to establish causality. Lastly, detailed 
information on sharing equipment of non-injection drugs was not collected in this 
study, which could be a risk factor of HCV infection. In order to elucidate HCV 
transmission in YMSM who reported drug use not including injection drug, further 
study is needed concentrated on MSM, with a larger sample size, with efforts to 
obtain HCV infection status for both the respondent and the sexual partner and 
information on sharing equipment of non-injection drugs. 
Despite the limitations mentioned above, this study has multiple strengths. First, this 
study analyzed dyadic data, which may provide insightful information among sexual 
partners regarding HCV infection. By incorporating and evaluating dyadic data, this 
study may infer characteristics of HCV transmission dynamics. Second, the study 
population, YMSM, represents a growing HCV susceptible subgroup, and the study 
results may add evidence of the emerging HCV epidemic in MSM in recent years. 
Third, the HIV, HCV, and syphilis infection status of participants were confirmed by 
lab test, not self-reported, which reduced the information bias.  
In conclusion, we found syphilis mono-infection, HIV mono-infection and syphilis/HIV 
co-infection were associated with increased risk of HCV infection among a sample of 
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YMSM living in Houston, who reported drug use not including injection drug use. 
Health education and promotion programs geared towards raising the awareness of 
HCV testing and treatment in HIV and/or syphilis infected YMSM may help reduce 
the disease burden of HCV directly. Also, programs targeting an increase in syphilis 
and HIV testing and treatment among YMSM may potentially reduce the 
transmission HCV in YMSM. 
 
Table 1 Sociodemographic characteristics and sexual risk behaviors of YMSM 
participants in Houston, TX (N=366) 
Covariates Total HCV+ HCV- Fisher test 
P value 
Total 366 (100) 12 (3.3) 354 (96.7)  
Age        0.519* 
    <25 186 (50.8) 5 (2.7) 181 (97.3) 
 
    ≥ 25 180 (49.2) 7 (3.9) 173 (96.1) 
 
Education level       0.795 
    High school or less 135 (36.9) 4 (3.0) 131 (97.0) 
 
    Above high school 231 (63.1) 8 (3.5) 223 (96.5) 
 
Hispanic       0.599 
    Yes 70 (19.1) 3 (4.3) 67 (95.7) 
 
    No 296 (80.9) 9 (3.0) 287 (97.0) 
 
Race       0.917 
    Black 230 (62.8) 8 (3.5) 222 (96.5) 
 
    White 83 (22.7) 2 (2.4) 81 (97.6) 
 
    Multiracial, other 53 (14.5) 2 (3.8) 51 (96.2) 
 
Working status       0.926 
    Full time 179 (48.9) 7 (3.9) 172 (96.1) 
 
    Part time 72 (19.7) 2 (2.8) 70 (97.2) 
 
    Not employed 115 (31.4) 3 (2.6) 112 (97.4) 
 
Homeless in the past 12 month       0.505 
    Yes 65 (17.8) 3 (4.6) 62 (95.4) 
 
    No 301 (82.2) 9 (3.0) 292 (97.0) 
 
Insurance       0.260 
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Covariates Total HCV+ HCV- Fisher test 
P value 
    Yes 217 (59.3) 9 (4.1) 208 (95.9) 
 
    No 149 (40.7) 3 (2.0) 146 (98.0) 
 
Ever been in jail for more than 24 hours       0.637 
    Yes 146 (39.9) 4 (2.7) 142 (97.3) 
 
    No 220 (60.1) 8 (3.6) 212 (96.4) 
 
Group sex       0.838 
    Yes 101 (27.6) 3 (3.0) 98 (97.0) 
 
    No 265 (72.4) 9 (3.4) 256 (96.6) 
 
No. of sexual partners in the past 6 months       0.933 
    0-1 104 (28.4) 4 (3.8) 100 (96.2) 
 
    2-5 162 (44.3) 5 (3.1) 157 (96.9) 
 
    >=6 100 (27.3) 3 (3.0) 97 (97.0) 
 
Continuous scale, include mean (SD, min, max)     
HIV infection       0.006 
    Yes 134 (37.1) 9 (6.7) 125 (93.3) 
 
    No 227 (62.9) 3 (1.3) 224 (98.7) 
 
Syphilis infection       <0.001 
    Yes 56 (15.7) 7 (12.5) 49 (87.5) 
 
    No 300 (84.3) 5 (1.7) 295 (98.3) 
 
Syphilis/HIV infection status    <0.001 
    Syphilis/HIV co-infection 43 (12.1) 6 (14.0) 37 (86.0)  
    Other a 313 (25.9) 6 (1.9) 307 (98.1)  
* P-value in Chi-square test. 
a Other: Syphilis mono-infection, HIV mono-infection, and neither syphilis nor HIV infection 
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Table 2 Characteristics perceived by participant of pairs of participants and sexual 
partners stratified by participants’ HCV infection status, Houston, TX (N=983) 
 
Covariates Total HCV+ HCV- Chi-
square 
test 
P value 
Sexual partner’s characteristics 
    Gender       0.299* 
        Male 904 (92.0) 31 (3.4) 873 (96.6) 
 
        Female or transgender 79 (8.0) 1 (1.3) 78 (98.7) 
 
    Education       0.374* 
        High school or less 299 (30.4) 11 (3.7) 288 (96.3) 
 
        Above high school 495 (50.4) 18 (3.6) 477 (96.4) 
 
        Unknown 189 (19.2) 3 (1.6) 186 (98.4) 
 
    Hispanic       0.630 
        Yes 208 (21.6) 8 (3.8) 200 (96.2) 
 
        No 757 (78.4) 24 (3.2) 733 (96.8) 
 
    Race       0.357 
        Black 501 (51.0) 19 (3.8) 482 (96.2) 
 
        White 297 (30.2) 6 (2.0) 291 (98.0) 
 
        Multiracial, other 185 (18.8) 7 (3.8) 178 (96.2) 
 
    Unprotected sex       0.519 
        Yes 436 (44.4) 12 (2.8) 424 (97.2) 
 
        No 201 (20.4) 9 (4.5) 192 (95.5) 
 
        Unknown 346 (35.2) 11 (3.2) 335 (96.8) 
 
    HIV infection status       0.276 
        Positive 108 (11.0) 6 (5.6) 102 (94.4) 
 
        Negative 614 (62.5) 20 (3.3) 594 (96.7) 
 
        Unknown 261 (26.6) 6 (2.3) 255 (97.7) 
 
    Ever use drugs       0.118* 
        Yes 384 (39.1) 17 (4.4) 367 (95.6) 
 
        No 378 (38.5) 12 (3.2) 366 (96.8) 
 
        Unknown 221 (22.5) 3 (1.4) 218 (98.6) 
 
Participant and sexual partner’s characteristics 
    Ever shared drug between the pair       0.071 
        Yes 287 (29.4) 14 (4.9) 273 (95.1) 
 
        No 688 (70.6) 18 (2.6) 670 (97.4) 
 
    Times that had sex between the pair       0.485 
        2-9 398 (41.5) 13 (3.3) 385 (96.7) 
 
        >=10 250 (26.1) 11 (4.4) 239 (95.6) 
 
        0-1 311 (32.4) 8 (2.6) 303 (97.4) 
 
    Whether had anal sex between the pair       0.665* 
        Yes 852 (88.2) 29 (3.4) 823 (96.6) 
 
        No 114 (11.8) 3 (2.6) 111 (97.4) 
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Covariates Total HCV+ HCV- Chi-
square 
test 
P value 
Whether the participant ever had receptive 
anal sex 
      0.853 
        Yes 494 (51.5) 17 (3.4) 477 (96.6) 
 
        No 465 (48.5) 15 (3.2) 450 (96.8) 
 
    Consistent condom use between the pair       0.306* 
        Yes 352 (35.8) 14 (4.0) 338 (96.0) 
 
        No 400 (40.7) 14 (3.5) 386 (96.5) 
 
        Unknown 231 (23.5) 4 (1.7) 227 (98.3) 
 
Whether use drugs before sex  
between the pair 
      0.077 
        Yes 292 (29.7) 14 (4.8) 278 (95.2) 
 
        No 691 (70.3) 18 (2.6) 673 (97.4) 
 
    Attended group sex together       0.122 
        Yes 81 (8.2) 5 (6.2) 76 (93.8) 
 
        No 902 (91.8) 27 (3.0) 875 (97.0) 
 
Homophily of participants and sexual partners 
    Age homophily       0.036 
        Participant ≤ Sexual partner 687 (69.9) 17 (2.5) 670 (97.5) 
 
        Participant > Sexual partner 296 (30.1) 15 (5.1) 281 (94.9) 
 
Race homophily 
(participant / sexual partner) 
      0.397 
        Black / Black 447 (45.5) 18 (4.0) 429 (96.0) 
 
        Black / non-Black 115 (11.7) 5 (4.3) 110 (95.7) 
 
        non-Black / Black 54 (5.5) 1 (1.9) 53 (98.1) 
 
        non-Black / non-Black 367 (37.3) 8 (2.2) 359 (97.8) 
 
HIV infection status homophily 
(participant / sexual partner a) 
      <0.001* 
        Positive/Positive 77 (7.9) 5 (6.5) 72 (93.5) 
 
        Positive/Negative 137 (14.0) 14 (10.2) 123 (89.8) 
 
        Positive/Unknown 109 (11.1) 6 (5.5) 103 (94.5) 
 
        Negative/Positive 31 (3.2) 1 (3.2) 30 (96.8) 
 
        Negative/Negative 475 (48.5) 6 (1.3) 469 (98.7) 
 
        Negative/Unknown 151 (15.4) 0 (0) 151 (100) 
 
  * P-value in Fisher exact test 
a Partner’s status as perceived by participant 
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Table 3 Results of bivariate GEE model of dyadic data of participant and sexual 
partner pairs in Houston, TX (N=983) 
 
Covariates Unadjusted Odds Ratio 
 (95%CI) 
P 
Participants’ characteristics 
    Age   0.535 
        ≥ 25 1.48 (0.46-4.77)   
        < 25 Reference   
    Education level   0.818 
        High school or less 0.87 (0.26-2.94)   
        Above high school Reference   
    Hispanic   0.694 
        Yes 1.36 (0.36-5.17)   
        No Reference   
    Race   0.802 
        White 0.64 (0.13-3.09)   
        Multiracial, other 1.08 (0.22-5.25)   
        Black Reference   
    Working status   0.811 
        Full time 1.53 (0.39-6.04)   
        Part time 1.05 (0.17-6.47)   
        Not employed Reference   
    Homeless in the past 12 months   0.602 
        Yes 1.49 (0.39-5.66)   
        No Reference   
    Insurance   0.251 
        Yes 2.05 (0.54-7.70)   
        No Reference   
    Ever been in jail for more than 24 hours   0.643 
        Yes 0.75 (0.22-2.54)   
        No Reference   
    Group sex   0.801 
        Yes 0.84 (0.22-3.15)   
        No Reference   
    No. of sexual partners in the past 6 months   0.841 
        0-1 1.52 (0.33-7.00)   
        2-5 1.04 (0.24-4.45)   
        >=6 Reference   
    HIV infection status   0.019 
        Yes 5.64 (1.49-21.29)   
        No Reference   
    Syphilis infection status   0.020 
        Yes 8.31 (2.53-27.28)   
        No Reference   
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Covariates Unadjusted Odds Ratio 
 (95%CI) 
P 
    Syphilis/HIV infection status   0.031 
        Syphilis/HIV co-infection 8.40 (2.57-27.46)   
        Other a Reference   
Sexual partners’ characteristics 
    Gender   0.406 
        Male 1.02 (0.97-1.08)   
        Female or transgender Reference   
    Education   0.307 
        High school or less 1.00 (0.97-1.04)   
        Unknown 0.98 (0.95-1.01)   
        Above high school Reference   
    Hispanic   0.654 
        Yes 1.00 (0.99-1.01)   
        No Reference   
    Race   0.892 
        White, other 1.00 (0.97-1.02)   
        Black Reference   
    Unprotected sex   0.705 
        Yes 0.99 (0.95-1.02)   
        Unknown 1.00 (0.96-1.03)   
        No Reference   
    HIV infection status   0.705 
        Positive 0.99 (0.95-1.02)   
        Unknown 1.00 (0.96-1.03)   
        Negative Reference   
    Ever use drugs   0.522 
        Yes 1.00 (0.98-1.03)   
        Unknown 0.98 (0.96-1.01)   
        No Reference   
Participant and sexual partner’s characteristics 
    Ever shared drug between the pair   0.374 
        Yes 1.01 (0.99-1.04)   
        No Reference   
    Times that had sex between the pair   0.396 
        2-9 1.00 (0.99-1.01)   
        >=10 1.01 (0.99-1.02)   
        0-1 Reference   
    Whether had anal sex between the pair   0.712 
        Yes 1.00 (0.99-1.02)   
        No Reference   
Participant in the bottom  
    when had anal sex between the pair 
  0.578 
        Yes 1.00 (0.99-1.02)   
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Covariates Unadjusted Odds Ratio 
 (95%CI) 
P 
        No Reference   
    Consistent condom use between the pair   0.384 
        Yes 1.01 (0.97-1.04)   
        Unknown 0.99 (0.97-1.02)   
        No Reference   
Whether use drugs before sex  
    between the pair 
  0.192 
        Yes 1.02 (0.99-1.06)   
        No Reference   
    Attended group sex together   0.436 
        Yes 2.13 (0.55-8.26)   
        No Reference   
Homophily of participants and sexual partners   
    Age homophily   0.117 
        Participant ≤ Sexual partner 0.96 (0.93-1.00)   
        Participant > Sexual partner Reference   
Race homophily 
    (participant / sexual partner) 
  0.952 
        Black / Black 1.26 (0.37-4.28)   
        Black / non-Black 1.23 (0.36-4.17)   
        non-Black / Black 0.99 (0.91-1.08)   
        non-Black / non-Black Reference   
HIV infection status homophily 
    (participant / sexual partner) 
  NA* 
 
*GEE model cannot estimate parameters due to small cell numbers. 
a Other: syphilis mono-infection, HIV mono-infection, and neither syphilis nor HIV infection 
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Table 4 Results of multivariable GEE model of the dyadic data  of participant and 
sexual partners pairs in Houston, TX (N=983) 
 
Parameter Adjusted Odds Ratio 
(95%CI) 
Age homophily  
    Participant ≤ sexual partner 0.76 (0.55-1.05) 
    Participant > sexual partner Reference 
HIV infection  
    Yes 2.76 (0.55-13.89) 
    No Reference 
Participant’s syphilis/HIV infection status  
    Syphilis/HIV co-infection 4.45 (1.05-18.76) 
    Other a Reference 
Participant and his sexual partner used drugs before sex  
    Yes 1.21 (0.85-1.71) 
    No Reference 
a Other: syphilis mono-infection, HIV mono-infection, and neither syphilis nor HIV 
infection 
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CONCLUSION 
In these three studies, we have provided epidemiological evidence that supports 
findings from previous studies that MSM who use drugs but not injection drugs 
(NIDU MSM) were at risk for HCV infection. (1) Overall HCV prevalence in NIDU 
MSM was higher than the rest of general population; (2) NIDU MSM >=42 years old 
had a higher risk of HCV infection than NIDU MSM <42 years old; (3) NIDU 
MSM >=42 years old who used >6 drugs were associated with increased probability 
of HCV infection among all NIDU MSM; (4) Among NIDU YMSM, syphilis mono-
infection, HIV mono-infection, and syphilis/HIV co-infection were associated with 
increased risk of HCV infection. 
The strength of our studies was the use of NIDU MSM data from two projects (DASH 
and YMAP) funded by NIDA and NIH. NIDU MSM in DASH project with a median 
age of 42 years, represented NIDU MSM of older generation, while NIDU MSM in 
YMAP project with a median age of 25 years represented NIDU MSM of younger 
generation. By comparing findings from these two data sources, we could compare 
characteristic that associated with HCV infection in different generations to some 
extent. We found that syphilis infection was associated with HCV infection in 
younger generation but not in older generation. One possible reason was that 
syphilis status was self-reported in DASH project, which may underestimate the 
effect of syphilis infection on HCV transmission. Another possible reason was that 
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syphilis infection was increasing fast in recent years, especially in young people, 
which reflected the increasing evidence of sexually transmitted HCV in recent years.  
The strength of our studies also included the use of two statistical approaches which 
were latent class analysis and dyadic data analysis to analyze NIDU MSM. Latent 
class analysis made it possible to analyze all information on drug use types in one 
analysis, by subgrouping the individuals using similar drug types. Dyadic data 
analysis incorporated characteristics of sexual partnership into the analysis. 
Although we could not identify statistically significant characteristics of sexual 
partnership related to HCV infection, it was the first study to use this approach for 
HCV study targeting NIDU MSM to the best of our knowledge.     
Our studies had some limitations, particularly those pertaining to sample size issue. 
Because our target population was hard-to-reach population, we could not obtain 
large sample size to guarantee enough statistical power. Also, the question related 
to sexual behavior and drug use behavior may also be underreported, which may 
lead to underestimating the effect of sexual behavior and drug use behavior on HCV 
transmission. 
Further study is warranted specifically among NIDU MSM, with a larger sample size, 
to more fully examine risk factors related to HCV infection, with efforts to obtain HCV 
infection status for both the participant and the sexual partner and information on 
sharing equipment of non-injection drugs. 
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Finally, we conclude that NIDU MSM >=42 years old with multiple drug use are at 
risk of HCV infection; YMSM with HIV mono-infection, syphilis mono-infection, and 
HIV/syphilis co-infection are at risk of HCV infection.  Health education should be 
promoted in these subgroups to enhance the awareness of HCV infection and 
increase HCV testing rates. In addition, treatment in HIV and/or syphilis infected 
YMSM may help reduce the disease burden of HCV directly. Also, programs 
targeting on increasing syphilis and HIV testing and treatment among YMSM may 
potentially reduce the transmission HCV in YMSM.  
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APPENDICES 
Appendix A:  Screening questionnaire for DASH project 
SCREENER             I.D.#_______________                                          Date: ____________ 
READ:  This is just a screener questionnaire.  The information obtained here is voluntary.  
You will not receive any money for answering these questions.  This information will be 
entered into our computer which will decide if you qualify.  Only if you qualify and finish the 
study will you receive any money. 
 
ASK ALL OF THESE QUESTIONS:        Montrose            Shotwell 
1. Race? _______________            2.  Male  or   Female            3.  How old are you? 
_________       
4.   What is your birthday?  ________-_________-________   
5.   Do you currently have a permanent address?               
Y      N  
      What is your address?________________________________Phone 
#________________ 
 Are you currently living in a shelter?     Y     N  Are you currently living on the 
street?    Y     N  
6.   Have you used crack cocaine in the last 48 hours?        Y    N                        # of 
times_______ 
7.   Have you used crack cocaine in the last 7 days?           Y     N                        # of 
times_______ 
8.   Have you used powder cocaine in the last 48 hours?     Y    N                        # of 
times_______ 
9.   Have you used powder cocaine in the last 7 days?       Y     N                         # of 
times_______ 
10.  Have you used heroin in the last 48 hrs?                      Y    N                        # of times 
_______ 
11.  Have you used heroin in the last  7 days?                     Y   N                         # of times 
_______ 
12.  Have you used marijuana in the last 48 hours?            Y    N                          # of 
times_______ 
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13.  Have you used marijuana in the last 7 days?               Y    N                          # of 
times_______ 
14.  Have you used meth (crystal) in the last 48 hrs?          Y   N                           # of 
times_______ 
15.  Have you used meth (crystal) in the last 7 days?         Y   N                           # of 
times_______ 
16.  Have you used alcohol in the last 48 hours?                Y    N                          # of 
times_______ 
17.  Have you used alcohol in the last 7 days?                    Y    N                         # of 
times_______ 
18. Have you ever injected drugs?     Y     N        # of times_______ in the past 30 days 
       Have you injected drugs in the last 7 days?     Y    N       
       Have you ever shared needles or works while injecting any drug?  Y     N      # of times 
past 30 days_____ 
       How many years have you injected drugs? _____________ 
19.  Do you smoke cigarettes?   Y     N                                   If yes, how many in a day? 
________ 
20.  Do you have a main sex partner?  Y   N 
21.  Have you had sex with a casual sex partner in the last week?   Y   N          
22.  Have you had sex with a new sex partner in the last week?       Y   N          
23.  Have you had vaginal/oral/anal sex in the last 48 hours?   List # of times for each 
         # vag_________   # oral___________   # anal___________          
        How many men?_________         How many women?_______ 
24.  Have you had vaginal/oral/anal sex in the last 7 days?        List # of times for each 
       # vag_________   # oral___________   # anal___________   
        How many men?_________          How many women?_______ 
 
25.  How many times have you had vaginal or anal sex in the last 30 days? ______ 
          How many men?_________          How many women?_______          
26.  Do you use condoms with all your partners?         Y     N    
27.  Of the people you had sex with, what percentage of them did you use a condom with? 
            None___  Quarter___  Half___  Three-quarters___  All___ 
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28.  Do you trade sex for money/drugs?     Y     N       If No, skip to Question 33 
29.  Have you traded sex for money/drugs in the last 48 hrs?   Y   N                    # of 
times_______ 
              How many men?_________               How many women?_______ 
30.  Have you traded sex for money/drugs in the last week?     Y   N                   # of 
times_______ 
              How many men?_________              How many women?_______ 
      Have you traded sex for money in the last 30 days?                  Y   N             # of 
times_______ 
              How many men?_________              How many women?_______ 
     Have you traded sex for drugs in the last 30 days?                     Y   N             # of 
times_______ 
              How many men?_________              How many women?_______ 
31.  What part of town do you normally work in?  ______________________________ 
32.  Do you work on the streets?  Y     N 
33.  Do you consider yourself: Gay____ Straight____ Bisexual_____            
34.  Have you ever been tested for HIV?     Y    N       Status?   Positive    Negative     Don’t 
Know   
       If HIV+, are you currently on meds? Y    N   Are you currently under a physician’s care?  
Y    N  
       If a vaccine was available for HIV, would you be willing to be vaccinated?                         
Y   N 
35. In your lifetime, have you ever been tested for a sexually transmitted disease?                 
Y     N 
 If yes, what types:  
 Syphilis___ Gonorrhea___ Chlamydia___ Genital Herpes___ Genital warts___ 
Other______ 
       In your lifetime, have you ever been diagnosed or treated with a sexually transmitted 
disease?   Y     N 
 If yes, what types:  
 Syphilis___ Gonorrhea___ Chlamydia___ Genital Herpes___ Genital warts___ 
Other______ 
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       If you were not treated, what was the reason? 
__________________________________________ 
36. Have you been vaccinated against hepatitis B?     Y    N 
If not, are you willing to be vaccinated against hepatitis B? Y     N 
37.  Have you ever been in drug treatment?    Y     N        # of times_______ 
38.  Have you ever received a transfusion with blood or blood products (including clotting 
factors)? Y     N                                          If yes, what was the year of your first 
transfusion? ________ 
39. Have you ever been employed as a medical, dental, public safety or other health care 
worker involved with human blood contact?      Y     N   
       What was your job description?_________________________________________ 
 What was your degree of blood contact?     Frequent_____              Infrequent_____ 
40.  Have you ever been in prison or jail for more than 24 hours?      Y    N 
Interviewer read:  I am going to ask you about a place where you may have smoked 
crack in the last 30 days.  One of the places I am going to ask you about is a place 
where someone pays money or gives the owner some crack to smoke at his/her 
place.  We call this kind of place a crack house.  What do you call such a place?  
_____ 
 
[Interviewer:  Record responses other than a ‘crack house.’  If the respondent calls a 
place where someone pays money or gives the owner some crack to smoke at his/her 
place by a different name, use that name in referring to a ‘crack house.’] 
 
41. In the past 30 days, how many times did you smoke crack in each of the following 
places?  
 At your home  _____ 
 At a friend’s home  _____ 
 At an acquaintance’s (someone you did not know well) home  _____ 
 In a crack house  _____ 
 In a bar  _____ 
 In a public place, like a park, alley, public restroom  _____ 
 Times 
If the response to smoking in a crack house was 0, skip to item ____.  If the response 
to smoking in a crack house is 1 or more times, ask: 
 
41a. When you smoked in a crack house, what was the usual number of people present 
during the times you were smoking? 
  1 other person _____ 
  2 to 3 other people _____ 
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  4 to 5 other people _____ 
  5 to 10 other people _____ 
  More than 10 other people _____ 
 
If the response to 41a is 1 other person, skip to 41c.  If the response is 2 or more 
people, ask: 
41b.  How many times did you smoke in a crack house when two or more persons were 
present? ____ 
  Times 
 
41c.  Of the ____ times you smoked in a crack house, how many times did you pay 
money to smoke there?  
  ____ 
  Times 
41d.  Of the ____ times you smoked in a crack house, how many times did you give the 
owner crack to smoke there?  ____ 
  Times 
41e.  Of the ____ times you smoked in a crack house, how many times did you have sex 
while you were there? 
   _____ 
  Times 
42.  How many people do you know have tuberculosis right now? _____ 
 Number 
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If the response to 42 is 0, skip to 42.  If two or more, go to 42b.  If the response is 1 
ask: 
42a.  What is the relationship of this person to you? 
 Relative _____ 
 Sex partner _____ 
 Someone you hang out with currently _____ 
 Someone you work with _____ 
 Someone that you were with in jail _____ 
 Someone you were in a shelter with _____ 
 Y/N 
42b.  How many people you know who have tuberculosis are related to you in  the 
following ways? 
 Relative _____ 
 Sex partner _____ 
 Someone you hang out with currently _____ 
 Someone you work with _____ 
 Someone that you were with in jail _____ 
 Someone you were in a shelter with _____ 
  number 
42c.  How many people do you know who are taking medication for tuberculosis right 
now? _____ 
 Number 
If the response to 42c is 0, skip to 43.  If two or more, go to 42e.  If the response is 1 
ask: 
42d.  What is the relationship of this person to you? 
 Relative _____ 
 Sex partner _____ 
 Someone you hang out with currently _____ 
 Someone you work with _____ 
 Someone that you were with in jail _____ 
 Someone you were in a shelter with _____ 
 Y/N 
42e.  How many people you know taking medications for tuberculosis are related to you 
in the following ways? 
 Relative _____ 
 Sex partner _____ 
 Someone you hang out with currently _____ 
 Someone you work with _____ 
 Someone that you were with in jail _____ 
 Someone you were in a shelter with _____ 
  number 
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43.  Who referred you to our study?  ________________________________________     
 
 
 
COMBO TEST RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
   HIV HBsAG HCV 
Positive    
Negative    
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